



# Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both *in-vitro* and *in vivo* models

Nilkumar Patel<sup>a,1</sup>, Nagavendra Kommineni<sup>a,1</sup>, Sunil Kumar Surapaneni<sup>a</sup>, Anil Kalvala<sup>a</sup>, Xuegang Yaun<sup>c,d</sup>, Aragaw Gebeyehu<sup>a</sup>, Peggy Arthur<sup>a</sup>, Leanne C. Duke<sup>b</sup>, Sara B. York<sup>b</sup>, Arvind Bagde<sup>a</sup>, David G. Meckes Jr<sup>b</sup>, Mandip Singh<sup>a,\*</sup>

<sup>a</sup> College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA

<sup>b</sup> Department of Biomedical Sciences, Florida State University College of Medicine, 1115 West Call Street, Tallahassee, FL, USA

<sup>c</sup> Department of Chemical and Biomedical Engineering, Florida State University, Tallahassee, FL, USA

<sup>d</sup> The National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL, USA

## ARTICLE INFO

### Keywords:

Cannabidiol

Extracellular vesicles

Sensitization

Doxorubicin and triple negative breast cancer

## ABSTRACT

Extracellular Vesicles (EVs) were isolated from human umbilical cord mesenchymal stem cells (hUCMSCs) and were further encapsulated with cannabidiol (CBD) through sonication method (CBD EVs). CBD EVs displayed an average particle size of  $114.1 \pm 1.02$  nm, zeta potential of  $-30.26 \pm 0.12$  mV, entrapment efficiency of  $92.3 \pm 2.21\%$  and stability for several months at  $4^\circ\text{C}$ . CBD release from the EVs was observed as  $50.74 \pm 2.44\%$  and  $53.99 \pm 1.4\%$  at pH 6.8 and pH 7.4, respectively after 48 h. Our *in-vitro* studies demonstrated that CBD either alone or in EVs form significantly sensitized MDA-MB-231 cells to doxorubicin (DOX) (\* $P < 0.05$ ). Flow cytometry and migration studies revealed that CBD EVs either alone or in combination with DOX induced G1 phase cell cycle arrest and decreased migration of MDA-MB-231 cells, respectively. CBD EVs and DOX combination significantly reduced tumor burden (\*\*\* $P < 0.001$ ) in MDA-MB-231 xenograft tumor model. Western blotting and immunocytochemical analysis demonstrated that CBD EVs and DOX combination decreased the expression of proteins involved in inflammation, metastasis and increased the expression of proteins involved in apoptosis. CBD EVs and DOX combination will have profound clinical significance in not only decreasing the side effects but also increasing the therapeutic efficacy of DOX in TNBC.

## 1. Introduction

Breast cancer (BC) is the second underlying cause of cancer-associated mortality among women and effective therapeutic management of triple negative breast cancer (TNBC; a subtype of basal-like BC) remains as a major clinical challenge due to recurrence and resistance (McKinney et al., 2020; Sun et al., 2017; Ma et al., 2020; Surapaneni et al., 2020; Surapaneni et al., 2018; Yin et al., 2020; Hedrick et al., 2016; Patel et al., 2015). Doxorubicin (DOX) is clinically used for the effective management of TNBC, but resistance remains as a concern due to autophagy, increased levels of ATP-binding cassette transporters and glutathione S-transferase and EMT (Pan et al., 2015; Tan, 2015; Zhao and Zhang, 2017; Ghanem et al., 2020). Despite liposomes have been

tried to improve and maximize the clinical efficacy of chemotherapeutic agents for TNBC, certain limitations like high production cost, poor stability and rapid clearance by the phagocytic system due to their recognition as a foreign substance even though they are similar to cell membrane limit their therapeutic usage (Andey et al., 2015; Griffin et al., 1993; Singh et al., 1989; Arthur et al., 2020; Li et al., 2011; Gulati et al., 1998; Ferdous et al., 1998; Gulati et al., 1998; Andey, 2015; Singh et al., 1989; Griffin, 1993; Boakye et al., 2015; Doddapaneni et al., 2016). Therefore, development of novel therapeutic strategies to combat TNBC is an unmet clinical need (Gu et al., 2021).

Recently, cannabinoids ( $\Delta^9$ -THC and CBD) are gaining enormous interest in cancer due to their potential effects on regulating cancer cell proliferation, metastasis, angiogenesis, and differentiation (Guzmán,

**Abbreviations:** EVs, Extracellular Vesicles; TNBC, triple negative breast cancer; CBD, cannabidiol; DOX, doxorubicin; DDS, drug delivery system; hUCMSCs, human Umbilical Cord Mesenchymal Stem Cells; NTA, nanoparticle tracking analysis; %EE, The percentage entrapment efficiency.

\* Corresponding author at: College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.

E-mail address: [mandip.sachdeva@gmail.com](mailto:mandip.sachdeva@gmail.com) (M. Singh).

<sup>1</sup> Nilkumar Patel and Nagavendra Kommineni should be considered joint first author.

<https://doi.org/10.1016/j.ijpharm.2021.120943>

Received 3 May 2021; Received in revised form 19 July 2021; Accepted 22 July 2021

Available online 27 July 2021

0378-5173/© 2021 Elsevier B.V. All rights reserved.

2003; Sarfaraz et al., 2008; Alexander et al., 2009; McAllister et al., 2011; Tomko et al., 2020; Greish et al., 2018). Accumulating evidence demonstrates the therapeutic efficacy of CBD in preclinical and clinical models of breast cancer (McAllister et al., 2011; Kenyon et al., 2018; Sultan et al., 2018; Elbaz et al., 2015; McAllister et al., 2007; Hernán Pérez de la Ossa et al., 2012). A recent study by García-Morales et al., has demonstrated that CBD decreased the IL-1 $\beta$  (i.e., an inflammatory cytokine) induced-invasiveness of breast cancer (García-Morales et al., 2020). CBD also induces autophagy, apoptosis, cell cycle arrest, and inhibits the migration, invasion, epithelial to mesenchymal transition (EMT) and angiogenesis of various tumors (Preet et al., 2011; Massi et al., 2013; Sreevalsan et al., 2011; Velasco et al., 2012). Cannabinoids are also used in combination with radiation therapy/anti-cancer drugs for various cancers (Torres et al., 2011; Scott et al., 2014; Fraguas-Sánchez et al., 2020; Nabissi et al., 2013).

Excessive first pass metabolism, poor solubility, and increased metabolism by CYP enzymes contribute to poor bioavailability of CBD and limit its clinical usage (Hunt et al., 1981; Watanabe et al., 2007; Zendulka, 2016). CBD is a small lipophilic molecule, which gets oxidized in basic media to quinones (Bruni et al., 2018; Mannila et al., 2007; Mojsa, 2019). Epidiolex® (i.e., a cannabidiol medication approved by USFDA to treat seizures) has shown oral bioavailability of only 13–19 % (Szaflarski et al., 2019; Millar et al., 2018; Zenone et al., 2020). Hence, improvement of oral bioavailability of CBD is a major clinical challenge and an unmet need. To date, various formulation approaches have been tried to overcome the problems of CBD. CBD loaded PLGA nanoparticles demonstrated anti-cancer effects in ovarian cancer by increasing the protein expression of cleaved PARP (Fraguas-Sánchez et al.,). CBD loaded microparticles displayed anti-cancer effects and improved the sensitivity of paclitaxel and doxorubicin in breast cancer (Fraguas-Sánchez et al., 2020).

Exosomes or small EVs (vesicles of 30–150 nm) are produced by the invagination of endosomal membranes (i.e., multivesicular bodies) and their subsequent fusion with plasma membrane (Brinton et al., 2015). Larger EVs are shed from the cell surface and called microvesicles. Recently, EVs have gained much attention for their potential use as drug delivery system (DDS) in various diseases (Fais et al., 2013; Zhang et al., 2019; Kwon et al., 2021). Apart from their extraordinary roles in mediating cell–cell communication, EVs (endogenous nanovesicles) are promising drug carriers for both hydrophilic (such as siRNAs and miRNAs) and hydrophobic drugs in cancer because of their high stability and biocompatibility (Kooijmans et al., 2012; Kalluri, 2016201620162016). EVs play a crucial role in proliferation, metastasis (EMT), angiogenesis, reprogramming of energy metabolism, immune regulation, transformation of non-neoplastic cells and chemoresistance (Osaki and Okada, 2019; Wee et al., 2019; Zhang et al., 2018). They also serve as diagnostic/prognostic markers in various cancers (Whiteside, 2016; Tai et al., 2018; Zhang, 2015). Mesenchymal stem cells (MSCs) show their therapeutic effects in various cancers majorly through EVs (Elahi et al., 2020; Crivelli et al., 2017). MSC-derived EVs can encapsulate various cargos (i.e., miRNAs, mRNAs, proteins and drugs), cross the plasma membrane for delivering cargos to their target sites and function either as tumor suppressors/promoters in various cancers depending upon the cell type (Yin et al., 2019; Lee et al., 2013).

EVs derived from hUCMSCs (hUCMSCs-EVs) are gaining tremendous attention due to their potential clinical applications in various conditions such as cancer, bronchopulmonary dysplasia, pulmonary hypertension, organ/tissue injury, stroke, liver fibrosis, wound healing, Alzheimer's disease, chronic kidney repair, liver fibrosis, acute inflammation and blood glucose level regulation by shuttling various bioactive components (proteins, lipids, mRNA, miRNA, and DNA) during mediation of cell–cell communication (Ma et al., 2017; Li et al., 2013; Goodarzi, 2018; Rani et al., 2015; Kommineni et al., 2021). These EVs show their clinical applications in regenerative medicine and serve as potential delivery tools for various chemotherapeutics (Cheng et al., 2017). Moreover, they have also shown their beneficial effects in peripheral

nerve injury models by modulating axonal outgrowth, vascular regeneration and neuroinflammation processes by decreasing inflammatory markers such as TNF- $\alpha$  and IL-1 $\beta$  (Dong et al., 2019; Shiue et al., 2019). Meanwhile, clinical applications require large number of cells or EVs, which cannot be manufactured in laboratory. Thus, multiple bioreactors have been designed to improve cell expansion for hMSC based therapy (Yuan et al., 2018; Tsai et al., 2020). However, EVs production through bioreactors with hMSC culture has not been widely reported as a potential feasible strategy.

As both CBD and hUCMSCs-EVs are well demonstrated in amelioration of cancer, in this study, we hypothesize that therapeutic usage of hUCMSCs-EVs generated from PBS-VW bioreactors would serve as an ideal delivery platform not only for improving the absorption and bioavailability for CBD but also for the reduction of CBD dosage required to achieve tumor regression. To the best of our knowledge, this is the first study demonstrating not only the formulation of CBD loaded EVs by using EVs derived from hUCMSCs but also the therapeutic effects of CBD loaded EVs in TNBC *in-vitro* and *in vivo*. In addition, this study demonstrates the efficacy of CBD EVs in improving the sensitivity of doxorubicin (DOX) in *in-vitro* and *in vivo* models of TNBC.

## 2. Materials and methods

### 2.1. Materials

CBD (GLP and GMP grade) was purchased from Purisys™ (Athens, GA). DOX was purchased from AK Scientific, Inc (Union City, CA). Dulbecco's Modified Eagle Medium (DMEM) and DMEM/Ham's F12 (1:1 Mixture) media were acquired from Millipore Sigma (St. Louis, MO). MDA-MB-231 cells (TNBC) were purchased from ATCC (Rockville, MD, USA). Fetal bovine serum (FBS) was procured from Thomas scientific (Swedesboro, NJ). VitroGel LDP2 hydrogel and Type 1 dilution buffer were received kindly from TheWell Biosciences (NJ, USA). MDA-MB-231 cells were cultured as previously described (Hedrick et al., 2015). Cells were used with passage number below 10. Bovine serum albumin (BSA), sucrose, ethanol, methanol, water (HPLC grade), Triton X-100, formaldehyde, phosphate buffered saline (PBS, 1X) were procured from Sigma Aldrich (St. Louis, MO). Human umbilical cord derived mesenchymal stem/stromal cells (hUCMSCs) of passage 0 to 2 were acquired from the Department of Chemical and Biomedical Engineering, Florida State University. PBS-vertical wheel bioreactor was purchased from PBS Biotech, Inc (Camarillo, CA). Cytodex-1 microcarrier was from VWR International (Radnor, PA).  $\alpha$ -MEM medium was purchased from Life Technologies (Carlsbad, CA). Sodium bicarbonate and Penicillin/Streptomycin were procured from ThermoFisher Scientific (Waltham, MA). 150 mm diameter petri dishes are from Corning (Corning, NY, USA). EVs free FBS was used for EVs collection and acquired by ultracentrifugation under 100,000 rcf, 4 °C for 20 h.

### 2.2. Animals

Female nude mice (5–6 weeks age) obtained from Envigo (Indianapolis, IN) were used for *in vivo* anti-tumor studies. Florida Agricultural and Mechanical University has AAALAC accredited animal facilities, and all the animal experiments carried out were reviewed and approved by the Institutional Animal Use and Care Committee of Florida Agricultural and Mechanical University (protocol number: 020–06) and complied with the NIH guidelines (Guide for the care and use of laboratory animals). All mice were euthanized via exposure to carbon dioxide (CO<sub>2</sub>).

## 3. Methods

### 3.1. Analytical method for quantification of cannabidiol (CBD)

The analytical method for CBD was developed by using RP-HPLC (Waters, USA) with a slight modification (Saingam and Sakunpak,

2018). Briefly, CBD was dissolved in methanol to obtain a stock solution of 1 mg/mL. A series of standards (0.5, 1, 2, 4, 8, 16 and 32 µg/mL) were prepared. Each Sample of 20 µL was injected and CBD was retained by a Symmetry® C18 column (150 × 3.9 mm, 5 µm). The mobile phase of methanol: water (85:15 % v/v) was used in an isocratic mode at a flow rate of 1 mL/min. The samples were detected using a Photodiode Array (PDA) detector (waters 2998) with a detection wavelength set at 220 nm.

### 3.2. Culture of hUCMSCs in PBS-vertical wheel (PBS-VW) bioreactors

hUCMSCs were cultured and expanded up to passage 4 in petri dishes in a standard 5 % CO<sub>2</sub> incubator with EV free complete culture medium (EV free CCM) containing α-MEM with 10 % EV free FBS, sodium bicarbonate and 1 % Penicillin/Streptomycin. Media was changed for every 2–3 days. Cells were grown to 80–90 % confluence and then trypsinized by using 0.25 % trypsin/EDTA to generate single cell suspension for bioreactor culture. Cells were seeded in PBS-VW bioreactor with 0.25 g of Cytodex-1 at the density of 1100–1500 cells/cm<sup>2</sup>. During initial seeding phase, medium volume used was 60 mL. The agitation was set to 25 rpm for 5 min and then under static condition for 15 min of 12 cycles for a period of 4 h. After initial seeding, medium volume was adjusted to 100 mL and the agitation speed was set to 25 rpm for further culture. Medium collection was performed every 2 days with 50 % fresh medium change. Sampling of bioreactor was performed every day, and 0.5 mL homogeneous suspension was taken from PBS-VW bioreactor under 25 rpm agitation. Cell morphology and expansion were visualized by Hoechst staining 33,342 (ThermoFisher) and imaged with an Olympus IX70 microscope using DAPI filter. Medium samples were centrifuged, and supernatant was collected for glucose and lactate measurement. Glucose and lactate concentrations were determined by YSI2950 biochemical analyzer (Yellow Spring, OH).

### 3.3. Isolation and purification of EVs from cell culture medium

Small EVs were isolated from cell-conditioned medium by modified differential centrifugation using polyethylene glycol (PEG) precipitation/concentration method as earlier described (Hurwitz et al., 2017; Hurwitz and Meckes, 2017; Hurwitz et al., 2018; Rider et al., 2016). EV pellet suspended in particle free PBS was characterized for NTA (nanoparticle tracking analysis) using ZetaView® BASIC NTA - Nanoparticle Tracking Video Microscope PMX-120, ZetaView software (version 8.05.11 SP4). EVs characterization was performed according to the minimal information for studies of EVs (MISEV) 2018 guidelines issued by the International Society for Extracellular Vesicles (Lötvall, et al., 2014; Witwer, 2017).

### 3.4. Preparation and optimization of CBD loaded EVs

CBD loaded EVs were prepared by two different methods (incubation and sonication). Briefly, blank EVs ( $1.5 \times 10^{11}$  particles/mL) taken in glass vials were added with 10 % w/v sucrose and 0.1 % w/v BSA on an ice bath and were further subjected to mild vortexing in order to dissolve the contents. The above EVs dispersion was incubated at 22/37 °C with ethanolic CBD at different concentrations (10 % w/w and 20 % w/w as per the protein content in EVs) for 2–3 h. After incubation, the EVs dispersion was evaluated for particle size, particle number and zeta potential by NTA and for free and entrapped CBD content (HPLC analysis). Similarly, CBD loaded EVs were formulated by sonication method using Branson Digital Sonifier 450 (MFG #100-132-888R), where blank EVs ( $1.5 \times 10^{11}$  particles/mL) were incubated with CBD solution (10 %, and 20 % w/w as per the protein content) and subjected to different sonication cycles (10–30 % Amplitude, 3 cycles of 30 s on/off for 2 min, 5 min-cooling between each cycle) at different buffer pH conditions (PBS-6.8 and 7.4 with and without 0.1 % (w/v) BSA along with 10 % sucrose solution) to get final optimized CBD loaded EVs. The obtained

formulations were evaluated for physical appearance in terms of precipitation/aggregation, particle size, particle number, zeta potential by NTA and free and encapsulated CBD.

### 3.5. Characterization of EVs

#### 3.5.1. Particle size and zeta potential

Average particle size (z-average) and zeta potential of CBD encapsulated EVs were analyzed by dynamic light scattering (DLS) technique at 25 °C with 90° scattering angle using NTA and Zeta View instrument (ZetaView® TWIN PMX-220) and the data was processed using Zeta-View Analysis software as previously described (Mehdiani et al., 2015). All the prepared EVs were diluted with particle free PBS at 1:1000 dilution and measured in triplicate.

#### 3.5.2. Morphological examination of CBD loaded EVs by TEM

The surface morphology of EVs were determined by Electron microscopy imaging according to the method as described by Lasser et al (Lässer et al., 2012). EVs protein content was estimated by using Pierce™ BCA Protein Assay Kit - Reducing Agent Compatible.

#### 3.5.3. Drug loading and entrapment efficiency

Theoretical CBD loading was varied from 10 to 20 % w/w for EVs. CBD present in EVs (entrapment efficiency) was determined by an ultrafiltration method using Vivaspin® 500 centrifugal filter unit (Sartorius, USA) followed by RP-HPLC analysis as per earlier report (Kommineni et al., 2021). The percentage entrapment efficiency (% EE) was calculated by using Eq. (1).

$$\% EE = \frac{\text{Amount of drug entrapped}}{\text{Total amount of drug taken}} \times 100 \quad (1)$$

#### 3.5.4. In-vitro CBD release from EVs

In-vitro drug release study was performed by a modified dialysis bag method as per earlier report (Kommineni et al., 2019; Kommineni et al., 2019; Kommineni, 2021). CBD loaded EVs dispersion (100 µg/mL) was sealed in a preactivated dialysis membrane pouch with molecular weight cut off (MWCO) of 12 kDa (Sigma-Aldrich, MO) and placed in 10 mL of release media (PBS, pH (6.8 and 7.4) containing 0.5 % tween 80) present in closed glass tubing which was kept in shaker bath (120 rpm at 37 °C). At predefined time intervals, sample of 1 mL was withdrawn, replaced with fresh medium to maintain sink condition and analyzed for CBD content by RP-HPLC.

#### 3.5.5. Stability studies

The optimized CBD loaded EVs were stored at  $4 \pm 3$  °C for 1 month and checked for particle size, zeta potential, and particle number by NTA and free and encapsulated CBD content was analyzed by HPLC method as described above.

### 3.6. Cell viability assay

MDA-MB-231 cells seeded in 96 well plates ( $6 \times 10^3$  cells/well) were treated with various concentrations of blank EVs, DOX, CBD and CBD EVs (0.1–10 µM) for 48 h. In another set of experiments, we performed cytotoxicity assay by using 1 µM CBD and 1 µM CBD EVs as a chemosensitizer for 24 h and followed by 48 h treatment with DOX (0.1–10 µM) followed by MTT staining as previously described (Arthur et al., 2020).

#### 3.6.1. 3D cell cultures and cytotoxic assay

The cytotoxic effects of CBD and CBD EVs in 3D non-printed cultures of MDA-MB-231 cells were evaluated according to the methods as described earlier (Arthur et al., 2020). After the fifth day of spheroids formation, cells were treated with different concentrations of CBD and CBD EVs for 48 h. Viability of the cells was determined using MTT assay.

### 3.6.2. Cell and tumor uptake studies for fluorescent EVs

Cell uptake studies were performed to evaluate the cell permeation ability of fluorescent EVs. Briefly, cells were seeded in a 6 well plate (5000 cells/well), incubated for 24 h and treated with fluorescent EVs (SYTO® RNASelect™ Green Fluorescent Cell Stain (S32703) Invitrogen™ Van Allen Way, Carlsbad, CA) for 48 h. Afterwards cells were washed thrice with PBS and fixed with 4 % v/v paraformaldehyde solution. 4, 6-diamidino-2-phenylindole (DAPI) was used for nuclei staining. Similarly, 100 µL of fluorescently labelled EVs were injected to mice by i.p. and after 5 h, the animal was sacrificed, and MDA-MB-231 tumor tissue was isolated. The isolated tissue was washed thoroughly in PBS and then 10-µm sections were prepared using a Cryotome (Shandon). The processed sections were stained with DAPI solution. Confocal laser scanning microscope (Leica TCS SP8 Laser Scanning Spectral Confocal Microscope) was used for capturing fluorescent images at 400x magnification.

### 3.6.3. Cell cycle analysis

MDA-MB-231 cells were seeded in 6 well plates ( $5 \times 10^5$  cells per well) and allowed to grow to 70–80 % confluency. Media was removed from the wells and after washing twice with PBS, the cells were treated with CBD, CBD EVs (1, 2.5, 5 µM) for 48 h. In another set, the cells were pre-sensitized with CBD and CBD EVs for 24 h followed by treatment with DOX (500 nM) for 48 h. After treatment, media was removed and the cells were washed twice with PBS, trypsinized by using 0.25 % trypsin-EDTA, centrifuged at  $300 \times g$  for 8–10 min and then the supernatant was removed. Fixation of the cells was carried out by using ice-cold 70 % v/v ethanol overnight at 4 °C. The suspension was centrifuged at  $300 \times g$  for 8–10 min and the supernatant was removed. The obtained cell pellet was resuspended in PBS and centrifuged at  $300 \times g$  for 8–10 min. Then the cells were treated with 100 µg/mL of RNase A for 30 min and suspended in 1 mL of propidium iodide (PI) staining buffer containing 50 µg/mL concentration of PI. The suspension was incubated in the dark for 30 min at room temperature and subsequently analyzed for DNA using BD FACS Calibur flow cytometer (BD Bioscience, Franklin Lakes, NJ). The percentage of cell-cycle distribution in G0/G1, S and G2/M phases of the cell cycle were quantified by using Flow Jo software version 7.6.1.

### 3.6.4. Cell migration assay

MDA-MB-231 cells were dissociated by using 0.25 % Trypsin-EDTA (Sigma) and seeded into the upper chamber of CIM-16 plates (40000 cells/well) in DMEM serum free medium. DMEM medium supplemented with 1 % FBS was added into the lower chamber as a chemoattractant. Impedance background measurement was initially assessed by adding 50 µL of cell culture medium into each well of the CIM-16 plate. CBD EVs (1 µM), DOX (500 nM) and CBD (1 µM) + DOX (500 nM) combination treatments were used in our study. A minimum of 4 wells per sample were placed according to the manufacturer's instructions and readings were taken every 10 min for a period of 40 h in xCELLigence label-free RTCA (real-time cell analysis) DP instrument (ACEA Biosciences, San Diego, CA, USA). The continuous and automatic electronic readout of cell-sensor impedance is displayed in real-time as Cell Index (a.u), a value which varies depending on the number of migrated cells into the lower chamber over the duration of Time (h).

### 3.6.5. Immunofluorescence and confocal microscopy

Immunocytochemistry was performed according to the methods as described earlier (Liu et al., 2014; Liu et al., 2006; Kalvala et al., 2020). After fixation and permeabilization, the cells were incubated with 3 % w/v BSA for 1 h at room temperature followed by staining with STAT-3 (anti rabbit), p-STAT3 (anti mouse) and anti-rabbit SP-1 (Cell Signalling Technologies, USA) for overnight at 4 °C by diluting the primary antibodies (1:100) in 3 % w/v BSA solution. Later, cells were washed thrice with PBST and then incubated with FITC conjugated anti-mouse secondary antibody (1:200 dilution) or red conjugated secondary antibody

(Santa Cruz Biotechnology Inc., CA, USA; 1:100 dilution) for 2 h in the dark at room temperature. Then, the cells were washed thrice with PBST and cover slips were finally mounted with NucBlue™ (ThermoFischer, USA) on a glass slide. Slides were subjected to confocal imaging using a confocal microscope (Leica TCS SP8 Laser Scanning Spectral Confocal).

### 3.7. Anti-tumor studies in TNBC athymic nude mice

MDA-MB-231 cells xeno-transplanted breast cancer model was used to evaluate the chemo sensitization effect of CBD and CBD EVs in combination with DOX. MDA-MB-231 cells (2.5 million in 100 µL of matrigel) were injected subcutaneously in nude mice and allowed to reach the tumor volume of 1000–1500 mm<sup>3</sup>. Animals were then subjected to randomized grouping (4 animals per each group) before treatment (Control, EVs, CBD, CBD EVs, CBD + DOX, CBD EVs + DOX). Animals were administered with CBD (5 mg/kg), EVs ( $\approx 10^{10}$ /mice), CBD EVs (5 mg/kg) by i.p route. However, in combination study CBD and CBD EVs were administered one day before the dosing of DOX (2 mg/kg, i.v.) to evaluate the chemosensitization effect. The treatment was continued for 2 weeks with twice a week treatment schedule. The tumor volume was measured periodically using vernier caliper and the tumor volumes were calculated by the formula Tumor volume =  $1/2 xy^2$ , where 'x' and 'y' represent the length and width of the tumors. The animals were euthanized, tumors were collected and processed for further analysis.

### 3.8. Immunoblotting

Tissue and cell proteins were extracted by using radio-immunoprecipitation assay (RIPA) lysis buffer to perform western blotting as reported earlier (Arthur et al., 2020; Arthur, 2020). Protein estimation was performed by using BCA Protein Assay Reagent kit. Equal concentration of protein was loaded and performed SDS PAGE gel electrophoresis and then electrophoretically transferred onto PVDF membrane by using Trans-Blot® Turbo™ Transfer System (Bio-Rad). Afterwards, the membrane was subjected to blocking for 1 h at room temperature by using PBS containing 0.1 % Tween 20 and 3 % w/v BSA. The membrane was incubated with primary antibodies {IL-17 (rabbit, 1:1000, Catalog no: 13838S, Cell Signaling Technology, USA),  $\beta$ -actin (rabbit, 1:1000, Catalog no: 4970S, Cell Signaling Technology, USA), NF- $\kappa$ B (rabbit, 1:1000, Catalog no: 8242S, Cell Signaling Technology, USA), Twist (rabbit, 1:1000, Catalog no: 69366S, Cell Signaling Technology, USA), STAT3 (rabbit, 1:1000, Catalog no: 12640S, Cell Signaling Technology, USA), p-STAT3 (mouse, 1:1000, Catalog no: SC-8059, Santa Cruz Biotechnology, USA), BAX (rabbit, 1:1000, Catalog no: 5023, Cell Signaling Technology, USA), Bcl2 (rabbit, 1:1000, Catalog no: 3498S, Cell Signaling Technology, USA), Cleaved Cas-3 (rabbit, 1:1000, Catalog no: 9661, Cell Signaling Technology), Integrin  $\alpha$ -5 (rabbit, 1:1000, Catalog no: 4705T, Cell Signaling Technology, USA), TGF- $\beta$  (rabbit, 1:1000, Catalog no: 3709, Cell Signaling Technology, USA), IL-6 (rabbit, 1:1000, Catalog no: 12153, Cell Signaling Technology, USA), Caspase-9 (rabbit, 1:1000, Catalog no: 9508, Cell Signaling Technology, USA), m-Tor (rabbit, 1:1000, Catalog no: 2983, Cell Signaling Technology, USA), GPC1 (rabbit, 1:1000, Catalog no: SAB1303133, Sigma-Aldrich, USA), GPC6 (rabbit, 1:1000, Catalog no: SAB1303579, Sigma-Aldrich, USA)} for overnight at 4 °C. The blots were washed thrice with PBS containing 0.1 % Tween-20 (PBST)) for 5 min each time, incubated with appropriate HRP-conjugated secondary antibodies {rabbit anti-mouse IgG (catalog number: 7076S; Cell Signaling Technology, USA); goat anti-rabbit IgG (catalog number: 7074S; Cell Signaling Technology, USA)} for 1 h room temperature followed by washing thrice with PBST for 5 min each time. The blots were incubated with Super Signal West Pico Chemiluminescent substrate and their images were captured using Chemidoc Instrument (Bio-Rad). The immunoblots were quantified by densitometry scanning using NIH ImageJ software (1.43u; <https://imagej.nih.gov/ij>).

### 3.9. HPLC analysis

RP-HPLC method was developed for CBD and the retention time was observed to be 3.53 min. The calibration curve (average peak area vs concentration) generated over the range of 0.1–32 µg/mL was found to be linear with a correlation coefficient of 0.9995, slope (78147), intercept (5548).


### 3.10. Statistical analysis

The values were represented as mean  $\pm$  SEM. The intergroup variations were measured by two tailed student's *t*-test or one-way ANOVA followed by "Bonferroni's Multiple Comparison Test" using the Graph Pad Prism, version 5.01. Results with *p* values < 0.05 were statistically significant.

## 4. Results

### 4.1. hUCMSCs growth and expansion in PBS-VW bioreactor

hUCMSCs were expanded in 2D planar culture and seeded in a microcarrier based, suspension culture system as PBS-VW bioreactor. As shown in Fig. 1A, initial seeding confirmed microscopically for 5–10 cells/microcarrier. hUCMSCs cell growth was also visualized in our study. Media samples were subjected to estimation of glucose and lactate concentrations, and we observed active metabolism of cells when they are grown in the PBS-VW bioreactors (Fig. 1B). Interestingly, glucose/lactate yield remained consistent at approximately 1.2, indicating that majority of the energy metabolism of hUCMSCs was relied on glycolysis in the PBS-VW bioreactor system (Fig. 1C).



**Fig. 1.** hUCMSCs cultured on Cytodex-1 microcarriers in PBS-VW bioreactor. A. Hoechst staining of hUCMSCs on microcarrier in PBS-VW bioreactor on Day 1, 3, 5 and 8. B. Glucose and lactate concentration for hUCMSCs in PBS-VW bioreactor. C. Weight ratio of glucose consumption over lactate production in the bioreactor system. D. Mean particle size distribution graph for CBD loaded EVs by sonication method. E. TEM image of EVs. F. Fluorescently labelled EVs uptake in MDA MB 231 cells. G. *In-vitro* CBD release from EVs in PBS at pH- 6.8 and 7.4 representing % cumulative CBD released Vs time.

#### 4.2. Characterization of EVs derived from human umbilical cord mesenchymal stem cells (hUCMSCs-EVs)

EVs were successfully isolated from different sources of media collected upon growing hUCMSCs in various conditions through differential centrifugation using extra-PEG precipitation technique. The isolated EVs were characterized by NTA for average particle size, particle number as well as zeta potential. The mean particle size of EVs collected from hUCMSCs grown in petri dishes was found to be  $144.75 \pm 5.12$  nm with an average particle number of  $6.8 \times 10^{10}$  particles/mL, and zeta potential of  $-58.98 \pm 4.56$  mV. The average estimated protein content by BCA assay kit was found to be  $199.46 \mu\text{g/mL}$ . In the next set of experiments, hUCMSCs were grown in multilayer flask and the isolation of EVs from the supernatant media was carried out by differential centrifugation method. The mean particle size of isolated EVs was found to be  $153.2 \pm 4.7$  nm, with an average particle number of  $2 \times 10^{11}$  particles/mL, zeta potential of  $-70.38 \pm 0.25$  mV and the estimated protein content of  $936 \mu\text{g/mL}$ . Electron microscopy was performed to confirm the presence of EVs. hUCMSCs-EVs and hUCMSCs-CBD EVs were observed to be small round particles with typical cup-shaped morphology (Fig. 1E). In addition, 0.1 Liter PBS-VW bioreactor was used to scaleup the EVs. Here, we used Cytodex 1 microcarriers, a support matrix which facilitates the growth of hUCMSCs in a bioreactor and allows culturing the cells for 1 week. The isolated media from the bioreactor was processed for differential centrifugation using PEG as a precipitating agent to enrich for EVs. The final recovered EVs were found with an average particle size of  $152.1 \pm 3.2$  nm, particle number ( $1.5 \times 10^{16}$  particles/mL), average protein concentration ( $2.32 \text{ mg/mL}$ ), and zeta potential of  $-38.61 \pm 0.01$  mV.

#### 4.3. Preparation and optimization of CBD loaded EVs

Initially CBD loaded EVs were formulated by simple incubation method. After loading of CBD into EVs, the free drug was removed by dialysis method as per earlier reports (Salarpour et al., 2019). The average particle size was found to be  $125.48 \pm 5.12$  nm with an entrapment efficiency of  $70.23 \pm 3.24$  % CBD (100  $\mu\text{g}$  is equivalent to 10 % drug loading according to the protein concentration) and zeta potential of  $-40.39 \pm 0.12$  mV and the average particle number ( $1.2 \times 10^{11}$  particles/mL). Alternatively, sonication was used to load CBD into EVs, and different parameters were optimized as mentioned in table 1. The prepared CBD loaded EVs formulations were stored at  $4^\circ\text{C}$  to check the stability in terms of physical appearance, particle size, zeta potential and particle number. The final optimized formulation parameters were observed to be: PBS with 0.1 % (w/v) bovine serum albumin (BSA) pH 7.4, 10 % w/w sucrose, with sonication conditions (20 % Amplitude (Amp), 3 cycles of 30 s on/off for a total of 2 min with a 5 min-cooling period between each cycle), followed by incubation at  $22/37^\circ\text{C}$  for 1 h. Herein, EVs with 10 % CBD loading was observed with an average particle size of  $114.1 \pm 1.02$  nm (Fig. 1D) and entrapment efficiency of  $92.3 \pm 2.21$  % and zeta potential of  $-30.26 \pm 0.12$  mV. Before sonication, the size of EVs were found to be  $146.43 \pm 2.12$  nm, with a zeta potential of  $-42.29 \pm 0.32$  mV. However, in other conditions there was a rapid precipitation and settling of protein was observed upon storage. At 20 % drug loading, precipitation of CBD as crystals was observed in the dispersion. The final optimized CBD EVs formulations were stored at  $4^\circ\text{C}$  and monitored for particle size and entrapment efficiency. After 1 month, we observed slight decrease in the particle size ( $109.8 \pm 0.98$  nm) with an entrapment efficiency of  $91.31 \pm 1.32$  % and zeta potential of  $-32.48 \pm 0.12$  mV.

#### 4.4. In vitro drug release from CBD loaded EVs:

In vitro drug release testing for CBD loaded EVs (100  $\mu\text{g/mL}$ ) was performed by dialysis method using cellulose acetate dialysis tubing at different pH conditions (6.8 and 7.4) in PBS. Sustained CBD release was

**Table 1**

Optimization parameters for the development of CBD loaded EVs.

Optimization Parameters	Variable Conditions	Stability on storage at $4^\circ\text{C}$
Buffer and pH Condition	PBS (6.8)	Unstable (Precipitation)
	PBS with 0.1 % (w/v) BSA (6.8)	Unstable (Precipitation)
	PBS (7.4)	Unstable (Precipitation)
Sonication cycles	PBS with 0.1 % (w/v) BSA (7.4)	<b>Stable</b>
	10 % Amp, 3 cycles of 30 s on/off for 2 min, 5 min-cooling between each cycle	Unstable (precipitation)
	20 % Amp, 3 cycles of 30 s on/off for 2 min, 5 min-cooling between each cycle	<b>Stable</b>
	30 % Amp, 3 cycles of 30 s on/off for 2 min with a 5 min-cooling between each cycle	Unstable (aggregation)
% CBD Loading	10	<b>Stable</b>
	20	Unstable
Incubation temperature	$22/37^\circ\text{C}$	<b>Stable</b>
Optimized formulation of CBD loaded EVs	Buffer: PBS with 0.1 % (w/v) BSA (7.4), Sonication: 20 % Amp, 3 cycles of 30 s on/off for 2 min, 5 min-cooling between each cycle, % CBD Loading: 10% w/w, Incubation temperature: $37^\circ\text{C}$	<b>Stable optimized formulation</b>


observed from EVs at both pH conditions. The percent cumulative CBD release was found to be  $50.74 \pm 2.44$  % at pH 6.8 after 24 h, however at pH 7.4 the percent cumulative CBD released was observed to be  $53.99 \pm 1.4$  % as shown in Fig. 1G.

#### 4.5. Effect of CBD EVs on cell viability

Cell viability assays were performed for CBD, blank EVs, CBD EVs, DOX against MDA-MB-231 cell line from 0.156 to 10  $\mu\text{M}$  concentrations and the  $\text{IC}_{50}$  values are represented in (Fig. 2). CBD and CBD EVs with 1  $\mu\text{M}$  concentration was selected to check the chemo sensitization effect in combination with DOX. MDA-MB-231 cells treated with blank EVs showed an average cell death of 20–25 %. CBD alone showed  $\text{IC}_{50}$  values of 3.72  $\mu\text{M}$  (Fig. 2A) and 23.66  $\mu\text{M}$  (Fig. 2E) in 2D and 3D cultures of MDA-MB-231 cells, respectively. However, CBD EVs showed  $\text{IC}_{50}$  values of 3.01  $\mu\text{M}$  (Fig. 2D) and 21.96  $\mu\text{M}$  in 2D and 3D cultures of MDA-MB-231 cells, respectively. MDA-MB-231 cells sensitized with 1  $\mu\text{M}$  concentration of CBD and CBD EVs for 24 h, followed by treatment with different concentrations of DOX for 48 h resulted in DOX  $\text{IC}_{50}$  values of 2.4  $\mu\text{M}$  (Fig. 2F) and 2.37  $\mu\text{M}$  (Fig. 2G) respectively.

#### 4.6. Cell cycle analysis

Flow cytometry of cell cycle analysis was performed after treating MDA-MB-231 cells with 5 different treatments [CBD (1  $\mu\text{M}$ ), CBD EVs (1  $\mu\text{M}$ ), DOX (500 nM), CBD (1  $\mu\text{M}$ ) + DOX (500 nM) and CBD EVs (1  $\mu\text{M}$ ) + DOX (500 nM)] to study the distribution of cells in different phases (G1, S and G2) and to detect the apoptotic cells with fractional DNA content. Both CBD EVs (1  $\mu\text{M}$ ) and CBD EVs (1  $\mu\text{M}$ ) + DOX (500 nM) combination significantly (\*\*P < 0.01 & \*\*\*P < 0.001) increased the cell population in sub G1 phase when compared to control groups (Fig. 3A-G). Additionally, DOX (500 nM) alone and CBD (1  $\mu\text{M}$ ) + DOX (500 nM) combination treatment significantly (\*P < 0.05) increased the percentage of cells in G1 phase when compared to control group, indicating that the cells are undergoing apoptosis.




**Fig. 2.** Cytotoxicity assay in MDA-MB-231 cells: A. % cell inhibition with CBD at different concentrations. B. % cell inhibition with DOX at different concentrations. C. % cell inhibition with blank EVs at different particles concentration in 2D cell cultures. D. % cell inhibition with CBD EVs at different concentrations. E. % cell inhibition with CBD at different concentrations in 3D cell cultures. F. % cell inhibition with presensitization of 1  $\mu$ M CBD in combination with DOX at different concentrations. G. % cell inhibition with presensitization of 1  $\mu$ M CBD EVs in combination with DOX at different concentrations.

#### 4.7. Effect of CBD EVs on expression of proteins involved in Inflammation, metastasis and apoptosis in MDA-MB 231 cells

Inflammation and metastasis play an important role in evading immune system surveillance and showing resistance to chemotherapy given for eradicating cancer cells as observed by increased expression of proteins involved in those processes by activating pro-survival strategies (Carceneri de Prati et al., 2017). Western blot analysis data revealed that CBD EVs (1  $\mu$ M) significantly decreased the expression of NF- $\kappa$ B, p-STAT3, STAT3, IL-17 and Twist proteins when compared to free CBD (1  $\mu$ M & 2.5  $\mu$ M) and control groups (Fig. 4A). Further, we also evaluated the effect of CBD and CBD EVs in improving the sensitivity of DOX by pre-treating MDA-MB 231 cells with CBD (1  $\mu$ M) and CBD EVs (1  $\mu$ M) for 24 h followed by treatment with DOX (500 nM) for 48 h. It was observed

that CBD EVs (1  $\mu$ M) + DOX (500 nM) combination significantly decreased the protein expression of NF- $\kappa$ B, p-STAT3, STAT3, IL-17, Bcl2 proteins and increased the expression of BAX protein when compared to control, DOX (500 nM) and CBD (1  $\mu$ M) + DOX (500 nM) (Fig. 4B). These findings were further validated by immunocytochemistry staining which confirmed that CBD EVs (1  $\mu$ M) + DOX (500 nM) decreased the expression of STAT3, p-STAT3, NF- $\kappa$ B and ITGA5 in MDA-MB-231 cells when compared to other groups (Fig. 5A, B & C). This suggests that CBD EVs either treated alone or in combination with DOX not only decreased the inflammation and metastasis but also facilitated apoptosis of MDA-MB-231 cells.




**Fig. 3.** Flow cytometry of cell cycle analysis. A. Representation of the flow histograms of A. CBD, B. CBD 1  $\mu$ M, C. CBD EVs 1  $\mu$ M, D. DOX, E. CBD + DOX, F. CBD EVs + DOX. B. Bar graphs showing cell cycle analysis after staining with propidium iodide (PI) in MDA-MB-231 cells treated with five different treatments and compared to control. All values are expressed as mean  $\pm$  SEM (n = 3). \*p < 0.05, \*\*\*p < 0.001 vs Control.

#### 4.8. Effect CBD EVs in MDA-MB-231 xenograft model of triple-negative breast cancer

Female Envigo nude mice were used to study the effect of blank EVs ( $\approx 10^{10}$ /mice; i.p), CBD (10 mg/kg; i.p), CBD EVs (5 mg/kg; i.p), DOX (2 mg/kg; i.v), CBD (5 mg/kg; i.p) + DOX (2 mg/kg; i.v), CBD EVs (5 mg/kg; i.p) + DOX (2 mg/kg; i.v) on tumor volume at different days of treatment and were compared with control group. We observed after 1st day of treatment, there was no significant difference in tumor volumes of different groups. However, on 4th day of treatment, there was a slight

difference in tumor volumes between the groups and the difference was significant as compared to control for CBD (10 mg/kg; \*P < 0.05), CBD EVs (5 mg/kg; \*P < 0.05), DOX (2 mg/kg; \*\*P < 0.01). Here, pre-sensitization with CBD EVs (5 mg/kg) significantly enhanced anti-tumor effect of DOX (2 mg/kg; \*\*\*P < 0.01). Similarly, at 10th day of treatment, DOX (2 mg/kg; \*\*P < 0.01) and combination groups, CBD + DOX (\*\*P < 0.01) and CBD EVs + DOX (\*\*\*P < 0.001) predominantly reduced the tumor burden in nude mice when compared to control group. After 2 weeks of treatment, CBD (\*\*P < 0.01), CBD EVs (\*\*P < 0.01) and DOX (\*\*\*P < 0.001) significantly reduced the tumor volume




**Fig. 4.** Effect of CBD loaded EVs on the expression of proteins involved in Inflammation, Metastasis and Apoptosis in MDA-MB-231 cells. A. Western blots and densitometric analysis of IL-17, NF-κB, Twist, P-STAT3/STAT3 proteins with free CBD and CBD EVs formulation treated MDA-MB-231 cells after 48 h. B. Western blots and densitometric analysis of BAX, Bcl2, IL-17, Twist, P-STAT3/STAT3 proteins in MDA-MB-231 cells after 48 h drug treatment with DOX alone, free CBD + DOX combination, and CBD EVs formulation + DOX. Data presented as means ± SEM, one-way ANOVA, \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  significant vs control.

in nude mice as compared to control (Fig. 6A). It was observed that EVs treatment alone has not induced any significant reduction in tumor volume when compared to control group. We observed that pre-sensitization of tumors with CBD (\*\* $P < 0.001$ ) and CBD EVs (\*\* $P < 0.001$ ) helped in reducing tumor volume by enhancing DOX uptake. From the above findings, we clearly observed that CBD EVs even at a dose of 5 mg/kg could reduce the tumor burden in TNBC nude mice model as compared to double the dose of free CBD treatment group. These findings were further supported by Fluorescent EVs uptake study in nude mice with MDA-MB-231 tumors. We observed high fluorescence intensity in the EVs treated tumor tissues (Fig. 6B).

#### 4.9. Effect of CBD EVs on apoptotic and inflammatory markers in MDA-MB-231 triple-negative breast cancer xenograft model

A variety of cytokines such as IL-6 and TGF-β play an important role in the process of inflammation and almost all of them make a network between tumor microenvironment (TME) and cancer cells, which further suppresses the immune response against tumor (Hedrick et al., 2016; Hartman et al., 2013). We have also evaluated the expression of proteins involved in NF-κB pathway in MDA-MB-231 tumor protein lysate. It was observed that CBD EVs (5 mg/kg) significantly decreased




**Fig. 5.** Effect of CBD loaded EVs on the expression of proteins involved in inflammation, migration and invasion in MDA-MB-231 cells. A. Immunocytochemical analysis of p-STAT3 & STAT3 in MDA-MB-231 cells treated with different drug treatments for 48 h. B. Immunocytochemical analysis of NF-κB in MDA-MB-231 cells treated with different drug treatments for 48 h. C. Immunocytochemical analysis of ITGA5 in MDA-MB-231 cells treated with different drug treatments for 48 h.

the expression of NF-κB and IL-17 when compared to control group (Fig. 7A). In addition, we noticed that CBD EVs (5 mg/kg) induced apoptosis by increasing the expression of Cleaved caspase-3 and BAX and decreasing the expression of Bcl2 respectively (Fig. 7A). Moreover, we observed that CBD EVs improved the sensitivity of DOX (western blot analysis of tumor protein lysate), which showed that CBD EVs (5 mg/kg) + DOX (2 mg/kg) combination significantly decreased the protein expression of IL-6, TGF-β and NF-κB when compared to control (untreated) group (Fig. 7B). Significant down regulation of Bcl2, mTOR and upregulation of BAX, cleaved caspase-3, and caspase-9 were also observed in CBD EVs (5 mg/kg) + DOX (2 mg/kg) treated tumors when compared to Control, DOX (2 mg/kg) and CBD (5 mg/kg) + DOX (2 mg/kg) group (Fig. 7B).

#### 4.10. CBD EVs formulation increased the sensitivity of DOX to reduce metastasis in MDA-MB-231 Triple-Negative breast cancer xenograft model and MDA-MB-231 cells

Migration, invasion and metabolism can determine the extent of metastasis of cancer cells. It is well known that CBD play an important role in modulation of TME (Elbaz et al., 2015). To investigate the role of CBD EVs formulation in improving the sensitivity to DOX, we have




**Fig. 6.** *In vivo* anti-tumor efficacy of CBD EVs formulation + DOX combination. A. Tumor volume. B. Tumor uptake studies for Fluorescent EVs. Data presented as means  $\pm$  SEM, one-way ANOVA, \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  significant vs control ( $n = 4$ ). Control group (animals did not receive fluorescent EVs), EVs treated tumor animals (mice received fluorescent EVs at  $1 \times 10^{11}$  particles/mL).

evaluated the expression of proteins which are involved in metastasis by using tumor protein lysate. It was observed that CBD EVs (5 mg/kg) and DOX (2 mg/kg) significantly reduced the expression of Integrin  $\alpha$ -5 (ITGA5), Twist, Glypican-1 (GPC1), Glypican-6 (GPC6) and Smad-2 in comparison to DOX (2 mg/kg), Control and CBD (5 mg/kg) + DOX (2 mg/kg) group (Fig. 8A). We also assessed the effect of CBD EVs (1  $\mu$ M) + DOX (500 nM) combination on the migration of MDA-MB-231 cells by using label-free real-time cell analysis platform (xCELLigence), which monitors the migration of cells for a period of 40 h. It was observed that CBD EVs (1  $\mu$ M) + DOX (500 nM) combination effectively decreased the migration of MDA-MB-231 cells when compared to control and other treatment groups (Fig. 8B).

## 5. Discussion and conclusions

### 5.1. Discussion


TNBC is the most prevalent form of malignancy and the leading cause of cancer related deaths in women in western world (Asad, 2021). Breast cancer associated deaths are due to metastasis of cancer cells to distant organs (i.e., lung, lymph nodes and bone), and chemotherapeutic drug resistance (Carty et al., 1995; Grobmyer, 2012). Despite the advances in chemotherapy for the management and prevention of TNBC progression, resistance and recurrence remains as major clinical concerns (Surapaneni et al., 2020; Li et al., 2017). Effective treatment strategies are necessary to eradicate drug resistance and deliver payload to the site



**Fig. 7.** Effect of CBD EVs formulation on Apoptotic and Inflammatory markers in MDA-MB-231 Triple-Negative Breast cancer Xenograft Model. A. Western blots and densitometric analysis of IL-17, NF-κB, Bcl2, BAX, Cleaved Cas-3 proteins in tumor tissue after drug treatment with CBD and CBD loaded EVs. B. Western blot and densitometric analysis of NF-κB, TGF-β, IL-6, Caspase 9, mTOR, Bcl2, BAX proteins in tumor tissue after drug treatment with DOX alone, free CBD + DOX combination, and CBD EVs formulation + DOX. Data presented as means  $\pm$  SEM, one-way ANOVA, \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  significant vs control.

of action in a tumor microenvironment. Trodelvy (sacituzumab govitecan-hziy), a monoclonal antibody, has been recently approved as a targeted (Trop-2 protein) precision medicine for metastatic TNBC (Seligson et al., 2020). Therapeutic potential of cannabinoids ( $\Delta$ 9-THC,  $\Delta$ 8-THC and CBD) is well demonstrated in lung cancer, glioma, leukemia, neuroblastoma, skin, uterus, breast, gastric, colorectal, pancreatic, and prostate carcinomas (Velasco et al., 2012). CBD, a phytocannabinoid from Hemp (*Cannabis sativa*) induces autophagy, apoptosis (Sultan et al., 2018); cell cycle arrest and inhibits the migration, invasion, epithelial to mesenchymal transition (EMT) and angiogenesis of various tumors by acting on CB1 and CB2 receptors, and TRPV1 ion channels and regulating ERK, MAPK, PI3K, p38, AKT and ceramide signaling pathways (Williamson and Evans, 2000; Seltzer et al., 2020). CBD interacts with G-protein-coupled receptors (Gi/o) and regulates various cellular signaling pathways by inhibition of adenylyl cyclase (Howlett and Shim, 2013). Excessive first pass metabolism, poor solubility and increased metabolism by CYP enzymes contribute to poor bioavailability of CBD and limit its clinical usage (Hunt et al., 1981; Watanabe et al., 2007; Zendulka, 2016).

EVs derived from hUCMSCs have been explored as potential candidates to deliver anticancer agents (Hurwitz and Meckes, 2017; Hurwitz et al., 2018). In this study, we isolated EVs from hUCMSCs expanded by multilayer flasks and PBS-VW bioreactor followed by differential



**Fig. 8.** CBD EVs formulation increased the sensitization of DOX in MDA-MB-231 cells *in vitro* and MDA-MB-231 xenograft model of TNBC. **A.** Western blots and densitometric analysis of Smad-2, GPC 6&1, ITGA5, Twist proteins in tumor tissue after drug treatment with DOX alone, free CBD + DOX combination, and CBD EVs formulation + DOX. **B.** Effect of CBD EVs and DOX combination on the migration of MDA-MB-231 cells. DOX (500 nM), CBD EVs (1 μM) and CBD EVs (1 μM) + DOX (500 nM) combination treated MDA-MB-231 cells were seeded in an xCelligence CIM-16 plate, and migration of the cells was monitored for 40 h and finally compared to untreated MDA-MB-231 cells; a.u., arbitrary units. Data presented as means ± SEM, one-way ANOVA, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 significant vs control.

centrifugation using extra-PEG precipitation technique. We observed that there was no significant difference in particle size of EVs isolated from the above-mentioned methods. However, we observed 2.94-fold and 4.7-fold difference in the particle number and protein content when EVs were isolated from multilayer culture when compared to monolayer cultures, respectively. In addition, PBS-VW bioreactor was utilized to scale up the cell expansion and EVs production, which displayed a 2.48-fold increase in EVs protein content when compared to the EVs isolated from multilayer culture. Similarly, the zeta potential of the EVs isolated from bioreactor was comparable and relatively more stable without aggregation at storage temperatures (2–8 °C) when compared to EVs isolated from monolayer and multilayer cultures. Generally, suspension culture in traditional bioreactors introduces potential stress to hMSCs which could damage cellular properties (Jeske et al., 2021; Wyrobnik et al., 2020). However, PBS-VW bioreactor potentially provide homogenous microenvironment to facilitate cell expansion while maintain low shear stress (Nogueira et al., 2019; Pinto et al., 2019). Thus, this microenvironment may also facilitate the production and cargo enrichment in the EVs. Although more studies are required to understand the effects of hydrodynamics on EVs biogenesis. Loading of drugs into EVs is a critical step and to date, multiple evidence

demonstrates usage of incubation, sonication and electroporation techniques for loading of paclitaxel (PTX), curcumin, miRNAs and siRNAs inside the EVs (Wang et al., 2021). In our study, initially we intended to compare the CBD loading and particle size difference in EVs after drug loading was carried out under both incubation and sonication methods. We optimized various parameters like buffer composition, pH, CBD loading, sonication cycles to get a superior optimized formulation. We observed that there was a 1.32-fold improvement in entrapment efficiency of CBD at 10 % loading using sonication in compared to incubation method. This may be due to enhanced permeabilization and interaction of lipophilic CBD with the EVs proteins. EVs loaded with CBD containing PBS, 0.1 % BSA and 10 % sucrose produced stable dispersion with a particle size of <130 nm and entrapment efficiency of more than 90 %. There was a slight decrease in particle size (10 nm) and entrapment efficiency (<5 %) upon storage for 1 month at refrigerated conditions (2–8 °C). The CBD release from EVs was evaluated by dialysis method, where we observed a sustained release of CBD (i.e., greater than 50 %) from the EVs at physiological buffer conditions, which mimics the environments of intestinal, extracellular matrix, blood and tumor cells. These observations corroborate well with earlier evidence, which demonstrates that paclitaxel loaded EVs have showed sustained release and superior anticancer effects *in vivo* (Pascucci et al., 2014).

In our study, we performed cytotoxicity assay of CBD and CBD EVs as well as the chemosensitization effect of CBD and CBD EVs in combination with DOX in 2D cultures of MDA-MB-231 cells. There was no significant difference between solution group as well as the EVs group, which is quite expected for *in-vitro* studies. Moreover, we observed there was a significant difference in G1 phase arrest when the MDA MB 231 wt cells were treated with CBD and CBD EVs as compared to control, suggesting that the cells are undergoing apoptosis.

Another important aspect of this research was to investigate the effect of same treatments in MDA-MB-231 Xenograft model of TNBC. Blank EVs have not shown any significant reduction in tumor volume as compared to control group. We assume that EVs were acting as delivery carriers for enhancing the effects of CBD to reduce the tumor burden in TNBC xenograft model. It was observed that CBD EVs + DOX combination significantly reduced the tumor burden when compared to control group, indicating better efficacy and promising clinical potential of CBD EVs + DOX. MDA-MB-231 cells treated with dye loaded EVs in 2D cultures have shown rapid increase in green fluorescence intensity. This suggests that the EVs could facilitate rapid internalization of cargo to the tumor cells possibly by endocytosis. Fluorescent EVs uptake study in MDA-MB-231 tumor tissue revealed presence of more EVs as observed by confocal microscopy. All these observations might be the reason for improved therapeutic efficacy of CBD when administered in EVs in our animal studies.

Inflammation plays a vital role in the development and progression of tumors (Greten and Grivnickov, 2019). Non-specific or specific inhibition of inflammatory mediators decrease the incidence and development of various cancers and thereby improved survivability (Ridker, 2017; Rothwell et al., 2012). Targeting inflammation is considered as a good approach for the therapy of various cancers (Ritter and Greten, 2019). Accumulating evidence suggests the anti-inflammatory potential of CBD in experimental models of various diseases (Hammell et al., 2016; Vuolo et al., 2019; Sangiovanni, 2019; Wang et al., 2017; dos-Santos-Pereira et al., 2020). We observed that CBD EVs (1 μM) or in combination of CBD EVs (1 μM) + DOX (500 nM) significantly decreased the expression of IL-17, STAT3 and p-STAT3, NF-κB proteins in MDA-MB-231 cells. Interestingly, we also observed decreased protein expression of IL-17, NF-κB and IL-6, TGF-β and NF-κB in tumor protein lysate of MDA-MB-231 cells when treated alone by CBD EVs (5 mg/kg) or in combination of CBD-EVs (5 mg/kg) and DOX (2 mg/kg) respectively.

Multiple evidence demonstrates that CBD inhibits the migration and invasion of various cancer cells (McAllister et al., 2011; Elbaz et al., 2015; Vaccani et al., 2005; Ramer et al., 2010). We also investigated the

effect of CBD EVs either alone or in combination with DOX on the migration of MDA-MB-231 cells by checking the expression of ITGA5, GPC1, GPC6, Smad-2 and Twist proteins. To date there are no reports showing the effect of CBD EVs either alone or in combination with DOX on GPC-1, -6, and ITGA5 in MDA-MB-231 cells. Smad-2 promotes the migration and invasion of various cancer cells (LV et al., 2013; Cao, 2016; Kumar et al., 2015). GPC1 regulates the proliferation, invasion and metastasis of tumor cells (Matsuda, 2001; Lund et al., 2020). GPC6 is well demonstrated to promote the migration, invasion and proliferation of nasopharyngeal carcinoma (Fan et al., 2019). Integrins decide the fate of cancer cells (i.e., whether to proliferate, die, migrate, or invade) in response to external stimuli (Guo and Giancotti, 2004; Stupack, 2005). Integrins play a vital role in the initiation and progression of breast cancer and regulation of stem cells biology (Hedrick et al., 2016; Pontier and Muller, 2009). Integrins are considered as novel therapeutic molecular targets in various cancer models (Aksorn and Chanvorachote, 2019; Tucker, 2006). ITGA5 regulates the adhesion, survival, and ECM component (i.e., fibronectin) mediated migration of breast cancer cells (Qin, 2011; Korah et al., 2004; Van der Velde-Zimmermann, 1997). ITGA5 is also associated with lung and bone metastasis in models of breast cancer (Yao et al., 2016; Ju et al., 2017; Pantano et al., 2021). In our study, western blot analysis data of tumor protein lysate revealed that CBD-EVs (5 mg/kg) and DOX (2 mg/kg) significantly reduced the expression of ITGA5 compared to Control, DOX (2 mg/kg) and CBD (5 mg/kg) + DOX (2 mg/kg) group. This was further confirmed by immunocytochemistry staining in 2D cultures of MDA-MB-231 cells. Twist mediates the metastasis and epithelial-mesenchymal transition of breast cancer cells (Kim et al., 2019; Cao et al., 2018; Zhang et al., 2018). It was observed that CBD EVs and DOX combination significantly decreased the expression of Smad-2, GPC1, GPC6, ITGA5 and Twist proteins. Further we also assessed the effect of CBD EVs and DOX combination on the migration of MDA-MB-231 cells by using label-free real-time cell analysis platform (xCELLigence), which monitors the migration of cells through noninvasive electrical impedance. It was observed that CBD EVs and DOX combination significantly decreased the migration of MDA-MB-231 cells. All these results demonstrate the efficacy of CBD EVs either alone or in combination with DOX in inhibiting the migration and invasion of cancer cells.

Apoptosis (i.e., programmed cell death) is characterized by a series of cellular events which finally lead to the activation of cysteine proteases called caspases. Cancer cells adopt several strategies to evade apoptosis (Fernald and Kurokawa, 2013). Dysregulation of apoptosis contributes to the development of cancer and chemotherapeutic drug resistance (Brown and Attardi, 2005). Determination of apoptotic processes disclose insights about the disease pathogenesis and the probable therapeutic options of how the disease can be effectively treated (Wong, 2011). BAX, Bcl2 and BAX/Bcl2 ratio serve as prognostic markers in various cancers (Kulsoom, 2018; Matsumoto, 2004; Khodapasand et al., 2015). BAX/Bcl2 ratio and Caspase-8 and 9 are involved in the resistance of breast cancer cells to paclitaxel (Sharifi et al., 2014). It was observed that CBD EVs (1  $\mu$ M) + DOX (500 nM) combination significantly increased the expression of BAX and decreased the expression of Bcl2 in 2d cultures of MDA-MB-231 cells, when compared to other treatment groups. These findings were further evaluated by using tumor protein lysate from MDA-MB-231 cells after drug treatment. It was observed that CBD-EVs (5 mg/kg) and DOX (2 mg/kg) significantly decreased the expression of Bcl2, m-TOR and increased the expression of BAX and Caspase 9 when compared to other treatment groups.

## 5.2. Conclusion:

CBD EVs formulation was successfully formulated with desired average particle size, good entrapment efficiency and zeta potential by sonication method using EVs derived from hUCMSCs. CBD EVs by itself or in combination with DOX decreased the inflammation, metastasis and facilitated apoptosis in MDA-MB-231 cells by G1 phase cell cycle arrest

and down regulation of IL-17, NF- $\kappa$ B, Twist, p-STAT3/STAT3 proteins *in-vitro*. Further, *in vivo* studies demonstrated that CBD EVs and DOX combination significantly reduced the tumor burden ( $P < 0.001$ ) at a dose of 5 mg/kg of CBD (5 mg/kg) which was superior to 10 mg/kg of free CBD. Further this combination modulated TME by decreasing the expression of TGF- $\beta$ , IL-6, NF- $\kappa$ B, ITGA5, Smad-2, GPC 1&6, Twist and mediated apoptosis by increasing the expression of BAX, Caspase 9 and decreasing the expression of Bcl2. Our studies suggested that CBD EVs increased the sensitivity of MDA-MB-231 tumor cells to DOX, thereby reducing the required effective dose of DOX thus abating or eliminating toxicity. Thus, EVs can be used as potential delivery systems for cannabinoids because of their easy internalization by tumors.

## CRediT authorship contribution statement

**Nilkumar Patel:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Nagavendra Kommineni:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Sunil Kumar Surapaneni:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Anil Kalvala:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Xuegang Yaun:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Aragaw Gebeyehu:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Peggy Arthur:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Leanne C. Duke:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Sara B. York:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Arvind Bagde:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Writing - review & editing. **David G. Meckes:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing. **Mandip Singh:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing - review & editing.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgements

Authors are thankful to the Consortium for Medical Marijuana Clinical Outcomes Research, Grant/Award number: SUB00002097, National Institute on Minority Health and Health Disparities of National Institutes of Health, Grant/Award Number: U54 MD007582 and NSF-CREST Center for Complex Materials Design for Multidimensional Additive Processing (CoManD), Grant/Award Number:1735968 for providing the funding for this research work.

## Data availability statement

The data that support the findings of our study are available from the corresponding author upon reasonable request.

## Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijpharm.2021.120943>.

## References

- Aksorn, N., Chanvorachote, P., 2019. Integrin as a molecular target for anti-cancer approaches in lung cancer. *Anticancer Res.* 39 (2), 541–548. <https://doi.org/10.21873/anticancer.13146>.
- Alexander, A., Smith, P.F., Rosengren, R.J., 2009. Cannabinoids in the treatment of cancer. *Cancer Lett.* 285 (1), 6–12.
- Andey, T., et al., 2015. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. *Mol. Pharm.* 12, 1105–1120.
- Andey, T., Sudhakar, G., Marepally, S., Patel, A., Banerjee, R., Singh, M., 2015. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. *Mol. Pharm.* 12 (4), 1105–1120. <https://doi.org/10.1021/mp5008629>.
- Arthur, P., et al., 2020. Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts. *Toxicol. Appl. Pharmacol.* 401.
- Arthur, P., Patel, N., Surapaneni, S.K., Mondal, A., Gebeyehu, A., Bagde, A., Kutlehria, S., Nottingham, E., Singh, M., 2020. Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts. *Toxicol. Appl. Pharmacol.* 401, 115112. <https://doi.org/10.1016/j.taap.2020.115112>.
- Asad, S., et al., 2021. Sociodemographic factors associated with rapid relapse in triple-negative breast cancer: a multi-institution study. *J. Natl. Compr. Canc. Netw.* 1, 1–8.
- Boakye, C.H.A., Patel, K., Singh, M., 2015. Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers. *Int. J. Pharm.* 489 (1–2), 106–116.
- Brinton, L.T., Sloane, H.S., Kester, M., Kelly, K.A., 2015. Formation and role of exosomes in cancer. *Cell. Mol. Life Sci.* 72 (4), 659–671.
- Brown, J., Martin, Attardi, Laura D., 2005. The role of apoptosis in cancer development and treatment response. *Nat. Rev. Cancer* 5 (3), 231–237. <https://doi.org/10.1038/nrc1560>.
- Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., Dosio, F., 2018. Cannabinoid delivery systems for pain and inflammation treatment. *Molecules* 23 (10), 2478. <https://doi.org/10.3390/molecules23102478>.
- Cao, W.H., et al., 2016. USP4 promotes invasion of breast cancer cells via Relaxin/TGF- $\beta$ 1/Smad2/MMP-9 signal. *Eur. Rev. Med. Pharmacol. Sci.* 20, 1115–1122.
- Cao, Jingying, Wang, Xin, Dai, Tao, Wu, Yuanzhong, Zhang, Meifang, Cao, Renxian, Zhang, Ruhua, Wang, Gang, Jiang, Rou, Zhou, Binhua P., Shi, Jian, Kang, Tiebang, 2018. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1. *Theranostics* 8 (10), 2739–2751. <https://doi.org/10.7150/thno.21477>.
- Carceneri de Prati, Alessandra, Butturini, Elena, Rigo, Antonella, Oppici, Elisa, Rossin, Michele, Boriero, Diana, Mariotto, Sofia, 2017. Metastatic breast cancer cells enter into dormant state and express cancer stem cells phenotype under chronic hypoxia. *J. Cell. Biochem.* 118 (10), 3237–3248. <https://doi.org/10.1002/jcb.v118.1010.1002/jcb.25972>.
- Carty, N.J., Foggett, A., Hamilton, C.R., Royle, G.T., Taylor, I., 1995. Patterns of clinical metastasis in breast cancer: an analysis of 100 patients. *Eur. J. Surg. Oncol. (EJSO)* 21 (6), 607–608.
- Cheng, L., Zhang, K., Wu, S., Cui, M., Xu, T., 2017. Focus on mesenchymal stem cell-derived exosomes: opportunities and challenges in cell-free therapy. *Stem Cells Int.* 2017, 1–10.
- Crivelli, B., Chlapanidas, T., Perteghella, S., Lucarelli, E., Pascucci, L., Brini, A.T., Ferrero, I., Marazzi, M., Pessina, A., Torre, M.L., 2017. Mesenchymal stem/stromal cell extracellular vesicles: from active principle to next generation drug delivery system. *J. Control. Release* 262, 104–117. <https://doi.org/10.1016/j.jconrel.2017.07.023>.
- Doddapaneni, R., Patel, K., Owaid, I.H., Singh, M., 2016. Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. *Drug Delivery* 23 (4), 1232–1241.
- Dong, R., Liu, Y., Yang, Y., Wang, H., Xu, Y., Zhang, Z., 2019. MSC-derived exosomes-based therapy for peripheral nerve injury: a novel therapeutic strategy. *Biomed. Res. Int.* 2019, 1–12.
- dos-Santos-Pereira, Mauricio, Guimarães, Francisco S., Del-Bel, Elaine, Raisman-Vozari, Rita, Michel, Patrick P., 2020. Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF- $\kappa$ B-dependent signaling and glucose consumption. *Glia* 68 (3), 561–573. <https://doi.org/10.1002/glia.v68.310.1002/glia.23738>.
- Elahi, F.M., Farwell, D.G., Nolte, J.A., Anderson, J.D., 2020. Concise review: preclinical translation of exosomes derived from mesenchymal stem/stromal cells. *Stem Cells* 38 (1), 15–21.
- Elbaz, M., Nasser, M.W., Ravi, J., Wani, N.A., Ahirwar, D.K., Zhao, H., Oghumu, S., Satoskar, A., Shilo, K., Carson, W.E., Ganju, R., 2015. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. *Mol. Oncol.* 9 (4), 906–919. <https://doi.org/10.1016/j.molonc.2014.12.010>.
- Fais, S., Logozzi, M., Lugini, L., Federici, C., Azzarito, T., Zarovni, N., Chiesi, A., 2013. Exosomes: the ideal nanovectors for biodelivery. *Biol. Chem.* 394 (1), 1–15. <https://doi.org/10.1515/hsz-2012-0236>.
- Fan, Chunmei, Tu, Chaofeng, Qi, Peng, Guo, Can, Xiang, Bo, Zhou, Ming, Li, Xiayu, Wu, Xu, Li, Xiaoling, Li, Guiyuan, Xiong, Wei, Zeng, Zhaoyang, 2019. GPC6 promotes cell proliferation, migration, and invasion in nasopharyngeal carcinoma. *J. Cancer* 10 (17), 3926–3932. <https://doi.org/10.7150/jca.31345>.
- Ferdous, A.J., Stemberge, N.Y., Singh, M., 1998. Role of monensin PLGA polymer nanoparticles and liposomes as potentiators of ricin A immunotoxins in vitro. *J. Control. Release* 50, 71–78.
- Fernald, Kaleigh, Kurokawa, Manabu, 2013. Evading apoptosis in cancer. *Trends Cell Biol.* 23 (12), 620–633.
- Fraguas-Sánchez, A.I., et al., 2020. PLGA nanoparticles for the intraperitoneal administration of cbd in the treatment of ovarian cancer: in vitro and in ovo assessment. *Pharmaceutics* 12. <https://doi.org/10.3390/pharmaceutics12050439>.
- Fraguas-Sánchez, A.I., Fernández-Carballido, A., Simancas-Herbada, R., Martín-Sabroso, C., Torres-Suárez, A.I., 2020. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. *Int. J. Pharm.* 574, 118916. <https://doi.org/10.1016/j.ijpharm.2019.118916>.
- Fraguas-Sánchez, A.I., Fernández-Carballido, A., Delie, F., Cohen, M., Martín-Sabroso, C., Mezzanatica, D., Fignini, M., Satta, A., Torres-Suárez, A.I., 2020. Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. *Eur. J. Pharm. Biopharm.* 154, 246–258. <https://doi.org/10.1016/j.ejpb.2020.07.008>.
- García-Morales, L., Castillo, A.M., Tapia Ramírez, J., Zamudio-Meza, H., Domínguez-Robles, M.D.C., Meza, I., 2020. CBD reverses the mesenchymal invasive phenotype of breast cancer cells induced by the inflammatory cytokine IL-1 $\beta$ . *Int. J. Mol. Sci.* 21 (7), 2429. <https://doi.org/10.3390/ijms21072429>.
- Ghanem, A., Emara, H.A., Muawia, S., Abd El Maksoud, A.I., Al-Karmalawy, A.A., Elshal, M.F., 2020. Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K/AKT/mTOR pathway and inhibition of topoisomerase II: in vitro and molecular docking studies. *New J. Chem.* 44 (40), 17374–17381.
- Goodarzi, P., et al., 2018. *Cell Biology and Translational Medicine* vol. 4, 119–131.
- Greish, K., Mathur, A., Al Zahran, R., Elkaissi, S., Al Jishi, M., Nazzal, O., Taha, S., Pittalà, V., Taurin, S., 2018. Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer. *J. Control. Release* 291, 184–195. <https://doi.org/10.1016/j.jconrel.2018.10.030>.
- Greten, Florian R., Grivennikov, Sergei I., 2019. Inflammation and cancer: triggers, mechanisms, and consequences. *Immunity* 51 (1), 27–41. <https://doi.org/10.1016/j.immuni.2019.06.025>.
- Griffin, T., et al., 1993. Potentiation of antitumor immunotoxins by liposomal monensin. *JNCI J. Natl. Cancer Inst.* 85, 292–298.
- Griffin, T., Rybak, M.E., Recht, L., Singh, M., Salimi, A., Raso, V., 1993. Potentiation of antitumor immunotoxins by liposomal monensin. *J. Natl. Cancer Inst.* 85 (4), 292–298. <https://doi.org/10.1093/jnci/85.4.292>.
- Grobmyer, S.R., et al., 2012. Nanoparticle delivery for metastatic breast cancer. *Nanomed. Nanotechnol. Biol. Med.* 8, S21–S30.
- Gu, X., Gao, Y., Wang, P., Wang, L., Peng, H., He, Y., Liu, Y., Feng, N., 2021. Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis. *J. Control. Release* 333, 374–390. <https://doi.org/10.1016/j.jconrel.2021.03.039>.
- Gulati, M., Grover, M., Singh, M., Singh, S., 1998. Study of azathioprine encapsulation into liposomes. *J. Microencapsul.* 15 (4), 485–494. <https://doi.org/10.3109/02652049809006875>.
- Gulati, M., Grover, M., Singh, M., Singh, S., 1998. Study of azathioprine encapsulation into liposomes. *J. Microencapsul.* 15, 485–494.
- Guo, Wenjun, Giancotti, Filippo G., 2004. Integrin signalling during tumour progression. *Nat. Rev. Mol. Cell Biol.* 5 (10), 816–826. <https://doi.org/10.1038/nrm1490>.
- Guzmán, M., 2003. Cannabinoids: potential anticancer agents. *Nat. Rev. Cancer* 3 (10), 745–755. <https://doi.org/10.1038/nrc1188>.
- Hammell, D.C., Zhang, L.P., Ma, F., Abshire, S.M., McIlwrath, S.L., Stinchcomb, A.L., Westlund, K.N., 2016. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. *Eur. J. Pain* 20 (6), 936–948. <https://doi.org/10.1002/ejp.818>.

- Hartman, Zachary C., Poage, Graham M., den Hollander, Petra, Tsimelzon, Anna, Hill, Jamal, Panupinthu, Nattapon, Zhang, Yun, Mazumdar, Abhijit, Hilsenbeck, Susan G., Mills, Gordon B., Brown, Powel H., 2013. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. *Cancer Res.* 73 (11), 3470–3480. <https://doi.org/10.1158/0008-5472.CAN-12-4524-T>.
- Hedrick, E., Lee, S.O., Doddapaneni, R., Singh, M., Safe, S., 2015. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. *Endocr. Relat. Cancer* 22, 831–840. <https://doi.org/10.1530/erc-15-0063>.
- Hedrick, E., Lee, S.O., Doddapaneni, R., Singh, M., Safe, S., 2016. NR4A1 Antagonists inhibit  $\beta$ 1-integrin-dependent breast cancer cell migration. *Mol. Cell Biol.* 36, 1383–1394. <https://doi.org/10.1128/mcb.00912-15>.
- Hedrick, E., Lee, S.O., Doddapaneni, R., Singh, M., Safe, S., 2016. NR4A1 antagonists inhibit  $\beta$ 1-integrin-dependent breast cancer cell migration. *Mol. Cell Biol.* 36 (9), 1383–1394.
- Hernández Pérez de la Ossa, D., Ligresti, A., Gil-Alegre, M.E., Aberturas, M.R., Molpeceres, J., Di Marzo, V., Torres Suárez, A.I., 2012. Poly- $\epsilon$ -caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy. *J. Control. Release* 161 (3), 927–932. <https://doi.org/10.1016/j.jconrel.2012.05.003>.
- Howlett, A.C., Shim, J.-Y., 2013. In: *Madame Curie Bioscience Database* (Internet) (Landes Bioscience).
- Hunt, C.A., Jones, R.T., Herning, R.I., Bachman, J., 1981. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. *J. Pharmacokinet. Biopharm.* 9 (3), 245–260.
- Hurwitz, S.N., Meckes, D.G., 2017. In: *Extracellular Vesicles*. Springer, pp. 303–317.
- Hurwitz, S.N., Nkosi, D., Conlon, M.M., York, S.B., Liu, X., Tremblay, D.C., Meckes, D.G., Longnecker, R.M., 2017. CD63 regulates Epstein-Barr virus LMP1 exosomal packaging, enhancement of vesicle production, and noncanonical NF- $\kappa$ B signaling. *J. Virol.* 91 (5) <https://doi.org/10.1128/JVI.02251-16>.
- Hurwitz, S.N., Cheerathodi, M.R., Nkosi, D., York, S.B., Meckes, D.G., Longnecker, R.M., 2018. Tetraspanin CD63 bridges autophagic and endosomal processes to regulate exosomal secretion and intracellular signaling of Epstein-Barr virus LMP1. *J. Virol.* 92 (5) <https://doi.org/10.1128/JVI.01969-17>.
- Jeske, Richard, Lewis, Shaquille, Tsai, Ang-Chen, Sanders, Kevin, Liu, Chang, Yuan, Xuegang, Li, Yan, 2021. Agitation in a microcarrier-based spinner flask bioreactor modulates homeostasis of human mesenchymal stem cells. *Biochem. Eng. J.* 168, 107947. <https://doi.org/10.1016/j.bej.2021.107947>.
- Ju, Julia A., Godet, Inès, Ye, I Chae, Byun, Jungmin, Jayatilaka, Hasini, Lee, Sun Joo, Xiang, Lisha, Samanta, Debangshu, Lee, Meng Horng, Wu, Pei-Hsun, Wirtz, Denis, Semenza, Gregg L., Gilkes, Daniele M., 2017. Hypoxia selectively enhances integrin  $\alpha$ (5) $\beta$ 1 receptor expression in breast cancer to promote metastasis. *Mol. Cancer Res.* 15 (6), 723–734. <https://doi.org/10.1158/1541-7786.MCR-16-0338>.
- Kalluri, R., 2016. The biology and function of exosomes in cancer. *J. Clin. Invest.* 126 (4), 1208–1215.
- Kalvala, Anil Kumar, Yerra, Veera Ganesh, Sherkhane, Bhoomika, Gundu, Chayanika, Arruri, Vijay, Kumar, Rahul, Kumar, Ashutosh, 2020. Chronic hyperglycemia impairs mitochondrial unfolded protein response and precipitates proteotoxicity in experimental diabetic neuropathy: focus on LonP1 mediated mitochondrial regulation. *Pharmacol. Rep.* 72 (6), 1627–1644. <https://doi.org/10.1007/s43440-020-00147-6>.
- Kenyon, Julian, Liu, Wai, Dalgleish, Angus, 2018. Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res.* 38 (10), 5831–5835. <https://doi.org/10.21873/anticancer.12924>.
- Khodapasand, E., Jafarzadeh, N., Farrokhi, F., Kamalidehghan, B., Houshmand, M., 2015. Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer? *Iran. Biomed. J.* 19, 69–75. <https://doi.org/10.6091/ibj.1366.2015>.
- Kim, Min Soo, Lee, Hyun Sook, Kim, Yun Jae, Lee, Do Yup, Kang, Sung Gyun, Jin, Wook, 2019. MEST induces Twist-1-mediated EMT through STAT3 activation in breast cancers. *Cell Death Differ.* 26 (12), 2594–2606. <https://doi.org/10.1038/s41418-019-0322-9>.
- Kommineni, N., et al., 2021. Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer. *Eur. J. Pharmac. Biopharm.* 158, 172–184.
- Kommineni, N., Meckes, D., Sachdeva, M., 2021. Exosome vehicles as nano-drug delivery materials for chemotherapeutic drugs. In: *Critical Reviews™ in Therapeutic Drug Carrier Systems*.
- Kommineni, Nagavendra, Mahira, Shaheen, Domb, Abraham, Khan, Wahid, 2019. Cabazitaxel-loaded nanocarriers for cancer therapy with reduced side effects. *Pharmaceutics* 11 (3), 141. <https://doi.org/10.3390/pharmaceutics11030141>.
- Kommineni, Nagavendra, Saka, Raju, Bulbake, Upendra, Khan, Wahid, 2019. Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer. *Chem. Phys. Lipids* 224, 104707. <https://doi.org/10.1016/j.chemphyslip.2018.11.009>.
- Kommineni, Nagavendra, Nottingham, Ebony, Bagde, Arvind, Patel, Nilkumar, Rishi, Arun K., Dev, Satyanarayan R.S., Singh, Mandip, 2021. Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer. *Eur. J. Pharm. Biopharm.* 158, 172–184. <https://doi.org/10.1016/j.ejpb.2020.11.007>.
- Kooijmans, S.A., Vader, P., van Dommelen, S.M., van Solinge, W.W., Schiffelers, R.M., 2012. Exosome mimetics: a novel class of drug delivery systems. *Int. J. Nanomed.* 7, 1525.
- Korah, R., Boots, M., Wieder, R., 2004. Integrin  $\alpha$ 5 $\beta$ 1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. *Cancer Res.* 64, 4514–4522. <https://doi.org/10.1158/0008-5472.Can-03-3853>.
- Kulsoom, B., et al., 2018. Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? *Cancer Manag. Res.* 10, 403–416. <https://doi.org/10.2147/cmar.S154608>.
- Kumar, K.J., Vani, M.G., Chueh, P.J., Mau, J.L., Wang, S.Y., 2015. Antrodin C inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via suppression of Smad2/3 and  $\beta$ -catenin signaling pathways. *PLoS One* 10. <https://doi.org/10.1371/journal.pone.0117111>.
- Kwon, S., Shin, S., Do, M., Oh, B.H., Song, Y., Bui, V.D., Lee, E.S., Jo, D.-G., Cho, Y.W., Kim, D.-H., Park, J.H., 2021. Engineering approaches for effective therapeutic applications based on extracellular vesicles. *J. Control. Release* 330, 15–30. <https://doi.org/10.1016/j.jconrel.2020.11.062>.
- Lässer, C., Eldh, M., Lötvall, J., 2012. Isolation and characterization of RNA-containing exosomes. *JoVE (J. Visual. Exp.)* e3037.
- Lee, J.-K., Park, S.-R., Jung, B.-K., Jeon, Y.-K., Lee, Y.-S., Kim, M.-K., Kim, Y.-G., Jang, J.-Y., Kim, C.-W., Shi, S., 2013. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. *PLoS ONE* 8 (12), e84256. <https://doi.org/10.1371/journal.pone.0084256>.
- Li, Zhen, Dong, Jian, Zou, Tianning, Du, Chengzhi, Li, Siyuan, Chen, Ceshi, Liu, Rong, Wang, Kunhua, 2017. Dexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Krüppel-like factor 5 in triple-negative breast cancer. *Oncotarget* 8 (7), 11555–11565. <https://doi.org/10.18632/oncotarget.v8i710.18632/oncotarget.14135>.
- Li, T., Yan, Y., Wang, B., Qian, H., Zhang, X.-u., Shen, L.-i., Wang, M., Zhou, Y., Zhu, W., Li, W., Xu, W., 2013. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. *Stem Cells Dev.* 22 (6), 845–854.
- Li, R.-J., Ying, X., Zhang, Y., Ju, R.-J., Wang, X.-X., Yao, H.-J., Men, Y., Tian, W., Yu, Y., Zhang, L., Huang, R.-J., Lu, W.-L., 2011. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. *J. Control. Release* 149 (3), 281–291. <https://doi.org/10.1016/j.jconrel.2010.10.019>.
- Liu, Xiaoying, Sun, Yu, Guo, Jianping, Ma, Hong, Li, Jiyou, Dong, Bin, Jin, Genglin, Zhang, Jianzhi, Wu, Jian, Meng, Lin, Shou, Chengchao, 2006. Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells. *Int. J. Cancer* 118 (8), 1922–1929. <https://doi.org/10.1002/ijc.21575>.
- Liu, Xiao-Fang, Yang, Wen-Ting, Xu, Rui, Liu, Jun-Tian, Zheng, Peng-Sheng, Asselin, Eric, 2014. Cervical cancer cells with positive Sox2 expression exhibit the properties of cancer stem cells. *PLoS ONE* 9 (1), e87092. <https://doi.org/10.1371/journal.pone.0087092>.
- Lötvall, J. et al., 2014. Wiley Online Library.
- Lund, M.E., Campbell, D.H., Walsh, B.J., 2020. The role of glypican-1 in the tumour microenvironment. *Adv. Exp. Med. Biol.* 1245, 163–176. [https://doi.org/10.1007/978-3-030-40146-7\\_8](https://doi.org/10.1007/978-3-030-40146-7_8).
- Lv, Z.-D., Kong, B., Li, J.-G., Qu, H.-L., Wang, X.-G., Cao, W.-H., Liu, X.-Y., Wang, Y., Yang, Z.-C., Xu, H.-M., Wang, H.-B., 2013. Transforming growth factor- $\beta$ 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition. *Oncol. Rep.* 29 (1), 219–225. <https://doi.org/10.3892/or.2012.2111>.
- Ma, J.H., Qin, L., Li, X., 2020. Role of STAT3 signaling pathway in breast cancer. *Cell Commun Signal* 18, 33. <https://doi.org/10.1186/s12964-020-0527-z>.
- Ma, J., Zhao, Y., Sun, L.-i., Sun, X., Zhao, X., Sun, X., Qian, H., Xu, W., Zhu, W., 2017. Exosomes derived from AKT-modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet-derived growth factor D. *Stem Cells Trans. Med.* 6 (1), 51–59.
- Mannila, J., Järvinen, T., Järvinen, K., Jarho, P., 2007. Precipitation complexation method produces cannabidiol/ $\beta$ -cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. *J. Pharm. Sci.* 96 (2), 312–319.
- Massi, P., Solinas, M., Cinquina, V., Parolaro, D., 2013. Cannabidiol as potential anticancer drug. *Br. J. Clin. Pharmacol.* 75 (2), 303–312. <https://doi.org/10.1111/bcp.12135.issue-210.1111/j.1365-2125.2012.04298.x>.
- Matsuda, K., et al., 2001. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. *Cancer Res.* 61, 5562–5569.
- Matsumoto, H., et al., 2004. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. *Jpn. J. Clin. Oncol.* 34, 124–130. <https://doi.org/10.1093/jcco/hyh026>.
- McAllister, S.D., Christian, R.T., Horowitz, M.P., Garcia, A., Desprez, P.-Y., 2007. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Mol. Cancer Ther.* 6 (11), 2921–2927. <https://doi.org/10.1158/1535-7163.MCT-07-0371>.
- McAllister, S.D., Murase, R., Christian, R.T., Lau, D., Zielinski, A.J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., Liu, Y., Debs, R.J., Moore, D.H., Desprez, P.-Y., 2011. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Res. Treat.* 129 (1), 37–47. <https://doi.org/10.1007/s10549-010-1177-4>.
- McKinney, S.M., Sieniek, M., Godbole, V., Godwin, J., Antropova, N., Ashrafian, H., Back, T., Chesus, M., Corrado, G.S., Darzi, A., Ettemadi, M., Garcia-Vicente, F., Gilbert, F.J., Halling-Brown, M., Hassabis, D., Jansen, S., Karthikesalingam, A., Kelly, C.J., King, D., Ledam, J.R., Melnick, D., Mostofi, H., Peng, L., Reicher, J.J., Romera-Paredes, B., Sidebottom, R., Suleyman, M., Tse, D., Young, K.C., De Fauw, J., Shetty, S., 2020. Addendum: International evaluation of an AI system for breast cancer screening. *Nature* 586 (7829), E19. <https://doi.org/10.1038/s41586-020-2679-9>.
- Mehdiani, Arash, Maier, Anatol, Pinto, Antonio, Barth, Mareike, Akhyari, Payam, Lichtenberg, Artur, 2015. An innovative method for exosome quantification and size measurement. *JoVE (J. Visual. Exp.)* (95). <https://doi.org/10.3791/50974>.

- Millar, S.A., Stone, N.L., Yates, A.S., O'Sullivan, S.E., 2018. A systematic review on the pharmacokinetics of cannabidiol in humans. *Front. Pharmacol.* 9, 1365.
- Mojisa, A.V., 2019. Google Patents.
- Nabissi, M., Morelli, M.B., Santoni, M., Santoni, G., 2013. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. *Carcinogenesis* 34, 48–57. <https://doi.org/10.1093/carcin/bgs328>.
- Nogueira, Diogo E.S., Rodrigues, Carlos A.V., Carvalho, Marta S., Miranda, Cláudia C., Hashimura, Yas, Jung, Sunghoon, Lee, Brian, Cabral, Joaquim M.S., 2019. Strategies for the expansion of human induced pluripotent stem cells as aggregates in single-use Vertical-Wheel™ bioreactors. *J. Biol. Eng.* 13 (1) <https://doi.org/10.1186/s13036-019-0204-1>.
- Osaki, M., Okada, F., 2019. Exosomes and their role in cancer progression. *Yonago Acta Medica* 62 (2), 182–190.
- Pan, Y.-Z., Wang, X., Bai, H., Wang, C.-B., Zhang, Q., Xi, R., 2015. Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin. *Genet. Mol. Res.* 14 (2), 5621–5629. <https://doi.org/10.4238/2015.May.25.14>.
- Pantano, Francesco, Croset, Martine, Driouch, Keltouma, Bednarz-Knoll, Natalia, Iuliani, Michele, Ribelli, Giulia, Bonnelle, Edith, Wikman, Harriet, Geraci, Sandra, Bonin, Florian, Simonetti, Sonia, Vincenzi, Bruno, Hong, Saw See, Sousa, Sofia, Pantel, Klaus, Tonini, Giuseppe, Santini, Daniele, Clézardin, Philippe, 2021. Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. *Oncogene* 40 (7), 1284–1299. <https://doi.org/10.1038/s41388-020-01603-6>.
- Pascucci, Luisa, Coccè, Valentina, Bonomi, Arianna, Ami, Diletta, Ceccarelli, Piero, Cusani, Emilio, Viganò, Lucia, Locatelli, Alberta, Sisto, Francesca, Doglia, Silvia Maria, Parati, Eugenio, Bernardo, Maria Ester, Muraca, Maurizio, Alessandri, Giulio, Bondiolotti, Gianpietro, Pessina, Augusto, 2014. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. *J. Control. Release* 192, 262–270.
- Patel, K., Chowdhury, N., Doddapaneni, R., Boakye, C.H.A., Godugu, C., Singh, M., 2015. Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative breast cancer. *J. Pharm. Sci.* 104 (12), 4417–4426.
- Pinto, Diogo, Bandejas, Cátia, Fuzeta, Miguel, Rodrigues, Carlos A.V., Jung, Sunghoon, Hashimura, Yas, Tseng, Rong-Jeng, Milligan, William, Lee, Brian, Ferreira, Frederico Castelo, Silva, Cláudia, Cabral, Joaquim M.S., 2019. Scalable manufacturing of human mesenchymal stromal cells in the vertical-wheel bioreactor system: an experimental and economic approach. *Biotechnol. J.* 14 (8), 1800716. <https://doi.org/10.1002/biot.v14.8.1002/biot.201800716>.
- Pontier, S.M., Muller, W.J., 2009. Integrins in mammary-stem-cell biology and breast-cancer progression—a role in cancer stem cells? *J. Cell Sci.* 122, 207–214. <https://doi.org/10.1242/jcs.040394>.
- Preet, A., Qamri, Z., Nasser, M.W., Prasad, A., Shilo, K., Zou, X., Groopman, J.E., Ganju, R.K., 2011. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. *Cancer Prev. Res. (Phila)* 4 (1), 65–75. <https://doi.org/10.1158/1940-6207.CAPR-10-0181>.
- Qin, L., et al., 2011. Steroid receptor coactivator-1 upregulates integrin  $\alpha$  expression to promote breast cancer cell adhesion and migration. *Cancer Res.* 71, 1742–1751. <https://doi.org/10.1158/0008-5472.Can-10-3453>.
- Ramer, Robert, Merkord, Jutta, Rohde, Helga, Hinz, Burkhard, 2010. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. *Biochem. Pharmacol.* 79 (7), 955–966. <https://doi.org/10.1016/j.bcp.2009.11.007>.
- Rani, S., Ryan, A.E., Griffin, M.D., Ritter, T., 2015. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. *Mol. Ther.* 23 (5), 812–823.
- Rider, M.A., Hurwitz, S.N., Meckes Jr, D.G., 2016. ExtraPEG: a polyethylene glycol-based method for enrichment of extracellular vesicles. *Sci. Rep.* 6, 23978.
- Ridker, P.M., et al., 2017. Effect of interleukin-1 $\beta$  inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet* 390, 1833–1842. [https://doi.org/10.1016/S0140-6736\(17\)32247-X](https://doi.org/10.1016/S0140-6736(17)32247-X).
- Ritter, B., Greten, F.R., 2019. Modulating inflammation for cancer therapy. *J. Exp. Med.* 216, 1234–1243. <https://doi.org/10.1084/jem.20181739>.
- Rothwell, Peter M, Wilson, Michelle, Price, Jacqueline F, Belch, Jill FF, Meade, Tom W, Mehta, Ziyah, 2012. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet* 379 (9826), 1591–1601. [https://doi.org/10.1016/S0140-6736\(12\)60209-8](https://doi.org/10.1016/S0140-6736(12)60209-8).
- Saingan, W., Sakunpak, A., 2018. Development and validation of reverse phase high performance liquid chromatography method for the determination of delta-9-tetrahydrocannabinol and cannabidiol in oromucosal spray from cannabis extract. *Revista Brasileira de Farmacognosia* 28 (6), 669–672.
- Salarpour, Soodeh, Forooshanfar, Hamid, Pournamdar, Mostafa, Ahmadi-Zeidabadi, Meysam, Esmaeili, Marzie, Pardakhty, Abbas, 2019. Paclitaxel incorporated exosomes derived from glioblastoma cells: comparative study of two loading techniques. *DARU J. Pharm. Sci.* 27 (2), 533–539.
- Sangiovanni, E., et al., 2019. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. *Phytother. Res.* 33, 2083–2093. <https://doi.org/10.1002/ptr.6400>.
- Sarfaraz, S., Adhami, V.M., Syed, D.N., Afaq, F., Mukhtar, H., 2008. Cannabinoids for cancer treatment: progress and promise. *Cancer Res.* 68, 339–342. <https://doi.org/10.1158/0008-5472.Can-07-2785>.
- Scott, K.A., Dalglish, A.G., Liu, W.M., 2014. The combination of cannabidiol and  $\Delta^9$ -tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. *Mol. Cancer Ther.* 13 (12), 2955–2967.
- Seligson, J.M., Patron, A.M., Berger, M.J., Harvey, R.D., Seligson, N.D., 2020. Sacituzumab Govitecan-hzy: an antibody-drug conjugate for the treatment of refractory, metastatic, triple-negative breast cancer. *Ann. Pharmacother.* 1060028020966548.
- Seltzer, Emily S., Watters, Andrea K., MacKenzie, Danny, Granat, Lauren M., Zhang, Dong, 2020. Cannabidiol (CBD) as a promising anti-cancer drug. *Cancers* 12 (11), 3203. <https://doi.org/10.3390/cancers12113203>.
- Sharifi, Simin, Barar, Jaleh, Hejazi, Mohammad Saeid, Samadi, Nasser, 2014. Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel. *Asian Pac. J. Cancer Prev.* 15 (20), 8617–8622. <https://doi.org/10.7314/APJCP.2014.15.20.8617>.
- Shiue, S.-J., Rau, R.-H., Shiue, H.-S., Hung, Y.-W., Li, Z.-X., Yang, K.D., Cheng, J.-K., 2019. Mesenchymal stem cell exosomes as a cell-free therapy for nerve injury-induced pain in rats. *Pain* 160 (1), 210–223. <https://doi.org/10.1097/j.pain.0000000000001395>.
- Singh, M., Ghose, T., Faulkner, G., Kralovec, J., Mezei, M., 1989. Targeting of methotrexate-containing liposomes with a monoclonal antibody against human renal cancer. *Cancer Res.* 49, 3976–3984.
- Sreevalsan, S., Joseph, S., Jutooru, I., Chadalapaka, G., Safe, S.H., 2011. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. *Anticancer Res.* 31, 3799–3807.
- Stupack, D G, 2005. Integrins as a distinct subtype of dependence receptors. *Cell Death Differ.* 12 (8), 1021–1030. <https://doi.org/10.1038/sj.cdd.4401658>.
- Sultan, A.S., Marie, M.A., Sheweita, S.A., 2018. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. *Breast* 41, 34–41. <https://doi.org/10.1016/j.breast.2018.06.009>.
- Sultan, A.S., Marie, M.A., Sheweita, S.A., 2018. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. *The Breast* 41, 34–41.
- Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., Zhu, H.-P., 2017. Risk factors and preventions of breast cancer. *Int J Biol Sci* 13 (11), 1387–1397. <https://doi.org/10.7150/ijbs.21635>.
- Surapaneni, S.K., Bashir, S., Tikoo, K., 2018. Gold nanoparticles-induced cytotoxicity in triple-negative breast cancer involves different epigenetic alterations depending upon the surface charge. *Sci. Rep.* 8, 12295. <https://doi.org/10.1038/s41598-018-30541-3>.
- Surapaneni, S.K., Bhat, Z.R., Tikoo, K., 2020. MicroRNA-941 regulates the proliferation of breast cancer cells by altering histone H3 Ser 10 phosphorylation. *Sci. Rep.* 10, 17954. <https://doi.org/10.1038/s41598-020-74847-7>.
- Szaflarski, J.P., Hermando, K., Bebin, E.M., Gaston, T.E., Grayson, L.E., Ampah, S.B., Moreadith, R., 2019. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. *Epilepsy Behav.* 95, 131–136.
- Tai, Y.-L., Chen, K.-C., Hsieh, J.-T., Shen, T.-L., 2018. Exosomes in cancer development and clinical applications. *Cancer Sci.* 109 (8), 2364–2374.
- Tan, Q., et al., 2015. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. *Cancer Sci.* 106, 1023–1032. <https://doi.org/10.1111/cas.12712>.
- Tomko, A.M., Whynot, E.G., Ellis, L.D., Dupré, D.J., 2020. Anti-cancer potential of cannabinoids, terpenes, and flavonoids present in cannabis. *Cancers (Basel)* 12 (7), 1985. <https://doi.org/10.3390/cancers12071985>.
- Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., García-Taboada, E., Barcia, J., Guzmán, M., Velasco, G., 2011. A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Mol. Cancer Ther.* 10 (1), 90–103.
- Tsai, A.C., Jeske, R., Chen, X., Yuan, X., Li, Y., 2020. Influence of microenvironment on mesenchymal stem cell therapeutic potency: from planar culture to microcarriers. *Front. Bioeng. Biotechnol.* 8, 640. <https://doi.org/10.3389/fbioe.2020.00640>.
- Tucker, Gordon C., 2006. Integrins: molecular targets in cancer therapy. *Curr. Oncol. Rep.* 8 (2), 96–103. <https://doi.org/10.1007/s11912-006-0043-3>.
- Vaccani, A., Massi, P., Colombo, A., Rubino, T., Parolaro, D., 2005. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *Br. J. Pharmacol.* 144, 1032–1036. <https://doi.org/10.1038/sj.bjp.0706134>.
- Van der Velde-Zimmermann, D., et al., 1997. Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via  $\alpha$ 5 $\beta$ 1 integrin. *Exp. Cell Res.* 230, 111–120. <https://doi.org/10.1006/excr.1996.3405>.
- Velasco, G., Sánchez, C., Guzmán, M., 2012. Towards the use of cannabinoids as antitumor agents. *Nat. Rev. Cancer* 12 (6), 436–444. <https://doi.org/10.1038/nrc3247>.
- Vuolo, Francieli, Abreu, Soraia C., Michels, Monique, Xisto, Débora G., Blanco, Natália G., Hallak, Jaime EC, Zuardi, Antonio W., Crippa, José A., Reis, Cardine, Bahl, Marina, Pizzichinni, Emílio, Maurici, Rosemeri, Pizzichinni, Marcia M.M., Rocco, Patricia R.M., Dal-Pizzol, Felipe, 2019. Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. *Eur. J. Pharmacol.* 843, 251–259. <https://doi.org/10.1016/j.ejphar.2018.11.029>.
- Wang, Jin, Chen, Derek, Ho, Emmanuel A., 2021. Challenges in the development and establishment of exosome-based drug delivery systems. *J. Control. Release* 329, 894–906.
- Wang, Yuping, Mukhopadhyay, Partha, Cao, Zongxian, Wang, Hua, Feng, Dechun, Haskó, György, Mechoulam, Raphael, Gao, Bin, Pacher, Pal, 2017. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. *Sci. Rep.* 7 (1) <https://doi.org/10.1038/s41598-017-10924-8>.
- Watanabe, K., Yamaori, S., Funahashi, T., Kimura, T., Yamamoto, I., 2007. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabidiol by human hepatic microsomes. *Life Sci.* 80 (15), 1415–1419. <https://doi.org/10.1016/j.lfs.2006.12.032>.

- Wee, I., Syn, N., Sethi, G., Goh, B.C., Wang, L., 2019. Role of tumor-derived exosomes in cancer metastasis. *Biochimica et Biophysica Acta (BBA)-Rev. Cancer* 1871 (1), 12–19.
- Whiteside, T.L., 2016. In: *Advances in Clinical Chemistry*, vol. 74, Elsevier, pp. 103–141.
- Williamson, Elizabeth M., Evans, Fred J., 2000. *Cannabinoids in clinical practice*. *Drugs* 60 (6), 1303–1314.
- Witwer, K.W. et al., 2017. Wiley Online Library.
- Wong, R.S., 2011. Apoptosis in cancer: from pathogenesis to treatment. *J. Exp. Clin. Cancer Res.* 30, 87. <https://doi.org/10.1186/1756-9966-30-87>.
- Wyrobnik, Tom A., Ducci, Andrea, Micheletti, Martina, 2020. Advances in human mesenchymal stromal cell-based therapies – towards an integrated biological and engineering approach. *Stem Cell Res.* 47, 101888. <https://doi.org/10.1016/j.scr.2020.101888>.
- Yao, Hongren, Veine, Donna M., Livant, Donna L., 2016. Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting  $\alpha 5 \beta 1$  integrin. *Breast Cancer Res. Treat.* 157 (3), 489–501. <https://doi.org/10.1007/s10549-016-3844-6>.
- Yin, L., Duan, J.J., Bian, X.W., Yu, S.C., 2020. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res.* 22, 61. <https://doi.org/10.1186/s13058-020-01296-5>.
- Yin, K., Wang, S., Zhao, R.C., 2019. Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. *Biomarker Res.* 7, 8.
- Yuan, X., Tsai, A.C., Farrance, I., Rowley, J., Ma, T., 2018. Aggregation of culture expanded human mesenchymal stem cells in microcarrier-based bioreactor. *Biochem. Eng. J.* 131, 39–46. <https://doi.org/10.1016/j.bej.2017.12.011>.
- Zendulka, O., et al., 2016. Cannabinoids and cytochrome P450 interactions. *Curr. Drug Metab.* 17, 206–226. <https://doi.org/10.2174/1389200217666151210142051>.
- Zenone, M., Snyder, J., Caulfield, T., 2020. Crowdfunding cannabidiol (CBD) for cancer: hype and misinformation on GoFundMe. *Am. J. Public Health* 110 (S3), S294–S299. <https://doi.org/10.2105/AJPH.2020.305768>.
- Zhang, X., et al., 2015. Exosomes in cancer: small particle, big player. *J. Hematol. Oncol.* 8, 83.
- Zhang, C., Ji, Q., Yang, Y., Li, Q.i., Wang, Z., 2018. Exosome: Function and role in cancer metastasis and drug resistance, 153303381876345 *Technol. Cancer Res. Treat.* 17. <https://doi.org/10.1177/1533033818763450>.
- Zhang, D.-R., Wang, W.-L., Wu, L.-X., Liu, M.-R., 2018. Twist promotes cell migration and invasion in human breast cancer cell line Hs578T. *Basic Clin. Med.* 38, 771.
- Zhang, M., Zang, X., Wang, M., Li, Z., Qiao, M., Hu, H., Chen, D., 2019. Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. *J. Mater. Chem. B* 7 (15), 2421–2433.
- Zhao, L., Zhang, B., 2017. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. *Sci. Rep.* 7, 1–11.